Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Rare Disease Trial Updates: September 2026

In September 2026, Trial Friend tracked 860 rare disease clinical trial updates across 114 conditions, including 3 FDA-related actions and 162 trial status changes, alongside enrollment updates and new trial site openings sourced from ClinicalTrials.gov and FDA announcements.

This is a permanent monthly archive. For the latest updates, see the live current events feed.

Major Updates: FDA Actions, Status Changes & Results

Status ChangeChronic Graft-versus-Host DiseaseSep 30thUniversity of GiessenNCT06409624
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeChronic Graft-versus-Host DiseaseSep 30thUniversity of Texas at AustinNCT05970341
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 30thSt. Olavs HospitalNCT06554886
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 30thVirginia Commonwealth UniversityNCT05580419
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDuchenne Muscular DystrophySep 30thSatellos Bioscience, Inc.NCT07287189
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDilated CardiomyopathySep 30thJoshua M HareNCT04476901
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDiffuse Intrinsic Pontine GliomaSep 30thUniversity of FloridaNCT04837547
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 30thNanordica Medical OUNCT06667752
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 30thBoston Children's HospitalNCT06611501
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 30thThe Danish Center for Expertise in RheumatologyNCT06299917
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 30thVirginia Commonwealth UniversityNCT05548452
No longer enrolling new participants

No longer enrolling new participants

Status ChangeBecker Muscular DystrophySep 29thSatellos Bioscience, Inc.NCT07287189
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAngelman SyndromeSep 29thIonis Pharmaceuticals, Inc.NCT06914609
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAmyotrophic Lateral SclerosisSep 29thCorcept TherapeuticsNCT05407324
No longer enrolling new participants

No longer enrolling new participants

FDA ApprovalMCT8 DeficiencySep 28th
FDA Approves First Treatment for MCT8 Deficiency

The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient

Status ChangeThyroid Eye DiseaseSep 27thMinghui Pharmaceutical (Hangzhou) LtdNCT07257185
No longer enrolling new participants

No longer enrolling new participants

Status ChangeStargardt DiseaseSep 27thAlkeus Pharmaceuticals, Inc.NCT02402660
No longer enrolling new participants

No longer enrolling new participants

Status ChangeNoonan SyndromeSep 26thBioMarin PharmaceuticalNCT06668805
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyotonic DystrophySep 25thDyne TherapeuticsNCT05481879
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple System AtrophySep 25thDyne TherapeuticsNCT05481879
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 25thAristotle University Of ThessalonikiNCT04806568
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 25thTG Therapeutics, Inc.NCT06143514
No longer enrolling new participants

No longer enrolling new participants

Status ChangeIgA NephropathySep 24thCalliditas Therapeutics ABNCT06712407
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 24thSun Yat-sen UniversityNCT05949944
No longer enrolling new participants

No longer enrolling new participants

Status ChangeIgG4-Related DiseaseSep 24thTongji HospitalNCT07339540
No longer enrolling new participants

No longer enrolling new participants

Status ChangeIdiopathic Pulmonary FibrosisSep 24thBoehringer IngelheimNCT06238622
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHunter SyndromeSep 24thAO GENERIUMNCT05208281
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 24thMemorial Sloan Kettering Cancer CenterNCT06756308
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHereditary AngioedemaSep 24thPharvaris Netherlands B.V.NCT06679881
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeGeographic AtrophySep 23rdAstellas Pharma Global Development, Inc.NCT06779773
No longer enrolling new participants

No longer enrolling new participants

Status ChangeFabry DiseaseSep 23rdGeneral University Hospital, PragueNCT07495410
Now recruiting (was Enrolling By Invitation)

Now recruiting (was Enrolling By Invitation)

Status ChangeCystic FibrosisSep 22ndChildren's Hospital Medical Center, CincinnatiNCT05517655
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndUniversity of Texas at AustinNCT04277117
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndSanofiNCT06290128
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndAstraZenecaNCT06942910
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndUniversity of ZurichNCT07524023
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndGuangdong Provincial People's HospitalNCT04381143
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndChildren's Hospital of PhiladelphiaNCT07425691
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndChildren's Hospital Medical Center, CincinnatiNCT04715685
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndUniversity of Illinois at ChicagoNCT07006818
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDuchenne Muscular DystrophySep 22ndNS Pharma, Inc.NCT05996003
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDuchenne Muscular DystrophySep 22ndInsmed Gene Therapy LLCNCT06817382
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDravet SyndromeSep 22ndLongboard PharmaceuticalsNCT06660394
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCystic FibrosisSep 22ndJaeb Center for Health ResearchNCT06449677
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCystic FibrosisSep 22ndHeidelberg UniversityNCT03925194
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Inflammatory Demyelinating PolyneuropathySep 22ndRigshospitalet, DenmarkNCT06040567
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndTampere UniversityNCT06286917
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndDavid RuttensNCT06890767
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndNorthwestern UniversityNCT05719714
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndRigshospitalet, DenmarkNCT06040567
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndPhilip Morris Products S.A.NCT07108166
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndUniversity of Illinois at ChicagoNCT06754280
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 22ndJaseng Medical FoundationNCT06591221
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCharcot-Marie-Tooth DiseaseSep 22ndRigshospitalet, DenmarkNCT06040567
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAmyotrophic Lateral SclerosisSep 21stHaukeland University HospitalNCT05095571
No longer enrolling new participants

No longer enrolling new participants

Status ChangeBecker Muscular DystrophySep 21stInsmed Gene Therapy LLCNCT06817382
No longer enrolling new participants

No longer enrolling new participants

Status ChangeBecker Muscular DystrophySep 21stNS Pharma, Inc.NCT05996003
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAmyotrophic Lateral SclerosisSep 21stCampus Bio-Medico UniversityNCT06834269
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAlport SyndromeSep 21stBayerNCT07211685
No longer enrolling new participants

No longer enrolling new participants

Status ChangeThalassemiaSep 19thBristol-Myers SquibbNCT05664737
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSpinal Muscular AtrophySep 19thUniversity of OxfordNCT07578454
No longer enrolling new participants

No longer enrolling new participants

Status ChangePulmonary Arterial HypertensionSep 18thIstanbul University - CerrahpasaNCT07667673
No longer enrolling new participants

No longer enrolling new participants

Status ChangeRetinitis PigmentosaSep 18thOctant, Inc.NCT07408232
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

FDA ApprovalSanfilippo SyndromeSep 17th
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.

Status ChangeMyelodysplastic SyndromesSep 17thNational Cancer Institute (NCI)NCT03816319
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesSep 17thInstitute of Hematology and Blood Transfusion, Czech RepublicNCT06765876
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 17thHoffmann-La RocheNCT05704361
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 17thTexas Woman's UniversityNCT07555015
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMedullary Thyroid CancerSep 17thNational Cancer Institute (NCI)NCT01660984
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thCelgeneNCT04884035
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thJacobs University Bremen gGmbHNCT06899308
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thFondazione Italiana Linfomi - ETSNCT05300282
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thM.D. Anderson Cancer CenterNCT06108232
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeHodgkin LymphomaSep 16thWake Forest University Health SciencesNCT05595577
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thMcMaster UniversityNCT06225232
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thTreeline Biosciences, Inc.NCT06733441
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thFred Hutchinson Cancer CenterNCT03779854
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 16thFondazione Italiana Linfomi - ETSNCT06492837
No longer enrolling new participants

No longer enrolling new participants

Status ChangePheochromocytomaSep 14thNational Cancer Institute (NCI)NCT01660984
No longer enrolling new participants

No longer enrolling new participants

Status ChangeParagangliomaSep 14thNational Cancer Institute (NCI)NCT01660984
No longer enrolling new participants

No longer enrolling new participants

Status ChangeShort Bowel SyndromeSep 14thTakedaNCT06973304
No longer enrolling new participants

No longer enrolling new participants

Status ChangePulmonary Arterial HypertensionSep 14thUniversity of GiessenNCT06409624
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangePolycythemia VeraSep 14thNovartis PharmaceuticalsNCT07340138
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelofibrosisSep 13thNovartis PharmaceuticalsNCT07340138
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesSep 13thSeagen, a wholly owned subsidiary of PfizerNCT04227847
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 13thNovartis PharmaceuticalsNCT06655896
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 13thNovartis PharmaceuticalsNCT06675864
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 13thUniversity of CalgaryNCT06261489
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeMultiple SclerosisSep 13thFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06551649
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple Endocrine Neoplasia Type 1Sep 13thJ.M. de LaatNCT05037461
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSanfilippo SyndromeSep 13thGC Biopharma CorpNCT06567769
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHunter SyndromeSep 12thDenali Therapeutics Inc.NCT05371613
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 12thGuangzhou Lupeng Pharmaceutical Company LTD.NCT06251180
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 12thOhio State University Comprehensive Cancer CenterNCT07166419
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 12thGenmabNCT06191744
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHemophilia ASep 11thHangzhou Gensciences Biopharmaceutical Co., Ltd.NCT07663903
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHemophilia ASep 11thNovo Nordisk A/SNCT05685238
No longer enrolling new participants

No longer enrolling new participants

Status ChangeGraves’ DiseaseSep 11thZai Lab (Shanghai) Co., Ltd.NCT07211776
No longer enrolling new participants

No longer enrolling new participants

Status ChangeEssential ThrombocythemiaSep 11thNovartis PharmaceuticalsNCT07340138
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thWilderman Medical ClinicNCT06916403
Status changed from Active Not Recruiting to Enrolling By Invitation

Status changed from Active Not Recruiting to Enrolling By Invitation

Status ChangeChronic Graft-versus-Host DiseaseSep 10thGruppo Italiano Malattie EMatologiche dell'AdultoNCT04282811
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thMedical University of South CarolinaNCT05095532
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCystic FibrosisSep 10thAstraZenecaNCT07245407
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thVejle HospitalNCT06473701
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thUniversity of PittsburghNCT06605807
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thFather Flanagan's Boys' HomeNCT06852664
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thEnsomaNCT06876363
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thCardiovascular and Interventional Radiological Society of EuropeNCT06149650
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thBoston UniversityNCT05503173
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thSanofiNCT06087627
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thWashington University School of MedicineNCT07020273
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thChang Gung University of Science and TechnologyNCT07310849
Now recruiting (was Enrolling By Invitation)

Now recruiting (was Enrolling By Invitation)

Status ChangeChronic Graft-versus-Host DiseaseSep 10thSoren Schou OlesenNCT06426160
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thUniversity of South CarolinaNCT06096701
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 10thBiocadNCT07119372
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCholangiocarcinomaSep 10thWashington University School of MedicineNCT06910670
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAngelman SyndromeSep 9thUltragenyx Pharmaceutical IncNCT07157254
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAngelman SyndromeSep 9thUltragenyx Pharmaceutical IncNCT06415344
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAmyotrophic Lateral SclerosisSep 9thFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06551649
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSpinal Muscular AtrophySep 8thCelgeneNCT06764485
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSystemic MastocytosisSep 8thFred Hutchinson Cancer CenterNCT03779854
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSpinocerebellar AtaxiaSep 8thKissei Pharmaceutical Co., Ltd.NCT07040137
No longer enrolling new participants

No longer enrolling new participants

Status ChangeParoxysmal Nocturnal HemoglobinuriaSep 7thSwedish Orphan BiovitrumNCT05776472
No longer enrolling new participants

No longer enrolling new participants

Status ChangeNeurofibromatosis Type 1Sep 6thDavid MillerNCT06515860
Status changed from Active Not Recruiting to Enrolling By Invitation

Status changed from Active Not Recruiting to Enrolling By Invitation

Status ChangeNarcolepsy Type 1Sep 6thTakedaNCT07363720
No longer enrolling new participants

No longer enrolling new participants

Status ChangeNarcolepsy Type 1Sep 6thTakedaNCT07299097
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesSep 6thAuron Therapeutics, Inc.NCT06846606
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeMyelodysplastic SyndromesSep 6thSwedish Orphan BiovitrumNCT05776472
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesSep 6thFred Hutchinson Cancer CenterNCT03779854
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyasthenia GravisSep 6thNovartis PharmaceuticalsNCT06704269
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyasthenia GravisSep 6thCartesian TherapeuticsNCT06799247
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 6thFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNCT06699095
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 6thAccelerated Cure Project for Multiple SclerosisNCT06441617
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeMultiple SclerosisSep 6thNovartis PharmaceuticalsNCT06617793
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 6thFondation Ophtalmologique Adolphe de RothschildNCT05999604
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisSep 6thNational Institute of Allergy and Infectious Diseases (NIAID)NCT05285891
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMixed Connective Tissue DiseaseSep 6thFred Hutchinson Cancer CenterNCT03779854
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMastocytosisSep 6thFred Hutchinson Cancer CenterNCT03779854
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHuntington DiseaseSep 5thHoffmann-La RocheNCT07246941
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 5thShanghai Junshi Bioscience Co., Ltd.NCT07081022
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 5thUniversity of WashingtonNCT06817122
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 5thNational Cancer Institute (NCI)NCT04739813
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaSep 5thBaylor College of MedicineNCT04288726
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHemophilia ASep 4thHangzhou Gensciences Biopharmaceutical Co., Ltd.NCT07684898
No longer enrolling new participants

No longer enrolling new participants

Status ChangeGranulomatosis with PolyangiitisSep 4thNovartis PharmaceuticalsNCT06868290
No longer enrolling new participants

No longer enrolling new participants

Status ChangeFibrodysplasia Ossificans ProgressivaSep 4thAmsterdam UMC, location VUmcNCT04307953
No longer enrolling new participants

No longer enrolling new participants

FDA ApprovalAlexander DiseaseSep 3rd
FDA Approves First Drug to Treat Alexander Disease

The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdRush University Medical CenterNCT06044649
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdEuropean Society of CardiologyNCT06495177
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdPardis Specialized Wellness InstituteNCT07591714
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdUniversity of Illinois at ChicagoNCT05275192
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdIl-Yang Pharm. Co., Ltd.NCT06665412
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdHealthPartners InstituteNCT07491861
No longer enrolling new participants

No longer enrolling new participants

Status ChangeEosinophilic EsophagitisSep 3rdDr. Falk Pharma GmbHNCT06596252
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDilated CardiomyopathySep 3rdTenaya TherapeuticsNCT05112237
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdUniversity of MichiganNCT06771713
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdJanssen Research & Development, LLCNCT05963074
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdStanford UniversityNCT06867757
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdConnect Biopharm LLCNCT06940154
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdUniversity Hospital, BrestNCT05299294
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdArizona State UniversityNCT06720909
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdAstraZenecaNCT06712563
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseSep 3rdMt. Sinai Medical Center, MiamiNCT03982693
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAmyotrophic Lateral SclerosisSep 2ndDallas VA Medical CenterNCT04244630
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAmyotrophic Lateral SclerosisSep 2ndFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNCT06856850
No longer enrolling new participants

No longer enrolling new participants

Trial Site & Enrollment Activity

sites_addedCongenital Adrenal HyperplasiaSep 30thCrinetics Pharmaceuticals Inc.NCT07159841
Added 1 new site: Chicago, Illinois

Added 1 new site: Chicago, Illinois

sites_addedCongenital Adrenal HyperplasiaSep 30thCrinetics Pharmaceuticals Inc.NCT07144163
Added 3 new sites: Campinas, Brazil, Halifax, Canada, Setagaya-ku, Japan

Added 3 new sites: Campinas, Brazil, Halifax, Canada, Setagaya-ku, Japan

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 30thSanofiNCT06859099
Added 3 new sites: Montpellier, France, Nice, France, Kodaira, Japan

Added 3 new sites: Montpellier, France, Nice, France, Kodaira, Japan

eligibility_changeChronic Inflammatory Demyelinating PolyneuropathySep 30thImmunovant Sciences GmbHNCT07032662
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thNovartis PharmaceuticalsNCT07354074
Added 26 new sites: New Brunswick, New Jersey, New York, New York, Cincinnati, Ohio and 23 more

Added 26 new sites: New Brunswick, New Jersey, New York, New York, Cincinnati, Ohio and 23 more

sites_removedChronic Graft-versus-Host DiseaseSep 30thMarche Region Regional Health AgencyNCT07149610
Reduced from 13 to 11 sites

Reduced from 13 to 11 sites

sites_addedChronic Graft-versus-Host DiseaseSep 30thSanofiNCT06082037
Added 9 new sites: Salt Lake City, Utah, Strasbourg, France, Milan, Italy and 6 more

Added 9 new sites: Salt Lake City, Utah, Strasbourg, France, Milan, Italy and 6 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thNational University of Natural MedicineNCT07125027
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thUniversity of GiessenNCT06409624
Added 1 new site: Bad Nauheim, Germany

Added 1 new site: Bad Nauheim, Germany

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 30thUniversity of GiessenNCT06409624
Target enrollment increased from 350 to 400

Target enrollment increased from 350 to 400

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thUniversity of GiessenNCT06409624
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thargenxNCT07091630
Added 66 new sites: Birmingham, Alabama, Rancho Mirage, California, Naples, Florida and 63 more

Added 66 new sites: Birmingham, Alabama, Rancho Mirage, California, Naples, Florida and 63 more

sites_removedChronic Graft-versus-Host DiseaseSep 30thImugene LimitedNCT03666000
Reduced from 23 to 15 sites

Reduced from 23 to 15 sites

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thImugene LimitedNCT03666000
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thVector Vitale LLCNCT06506643
Added 1 new site: Kropyvnytskyi, Ukraine

Added 1 new site: Kropyvnytskyi, Ukraine

sites_addedChronic Graft-versus-Host DiseaseSep 30thTakedaNCT06948318
Added 5 new sites: San Diego, California, New York, New York, The Bronx, New York and 2 more

Added 5 new sites: San Diego, California, New York, New York, The Bronx, New York and 2 more

sites_addedChronic Graft-versus-Host DiseaseSep 30thUCB Biopharma SRLNCT07725939
Added 2 new sites: Hangzhou, China, Shijiazhuang, China

Added 2 new sites: Hangzhou, China, Shijiazhuang, China

sites_addedChronic Graft-versus-Host DiseaseSep 30thKedrion S.p.A.NCT06752356
Added 2 new sites: Stamford, Connecticut, Miami, Florida

Added 2 new sites: Stamford, Connecticut, Miami, Florida

sites_addedChronic Graft-versus-Host DiseaseSep 30thAusper Biopharma Co., Ltd.NCT07069569
Added 13 new sites: Chongqing, China, Fuzhou, China, Guangzhou, China and 10 more

Added 13 new sites: Chongqing, China, Fuzhou, China, Guangzhou, China and 10 more

sites_addedChronic Graft-versus-Host DiseaseSep 30thBoston Scientific CorporationNCT06827262
Added 3 new sites: Stanford, California, Saint Cloud, Minnesota, The Bronx, New York

Added 3 new sites: Stanford, California, Saint Cloud, Minnesota, The Bronx, New York

sites_addedDuchenne Muscular DystrophySep 30thAvidity Biosciences, Inc.NCT07587242
Added 2 new sites: Milan, Italy, Leiden, Netherlands

Added 2 new sites: Milan, Italy, Leiden, Netherlands

Enrollment UpdateDilated CardiomyopathySep 30thJoshua M HareNCT04476901
Target enrollment decreased from 136 to 107

Target enrollment decreased from 136 to 107

sites_addedDiffuse Intrinsic Pontine GliomaSep 30thNational Cancer Institute (NCI)NCT05099003
Added 1 new site: Temple, Texas

Added 1 new site: Temple, Texas

sites_addedDesmoplastic Small Round Cell TumorSep 30thNational Cancer Institute (NCI)NCT04616560
Added 2 new sites: Valhalla, New York, Portland, Oregon

Added 2 new sites: Valhalla, New York, Portland, Oregon

sites_addedDermatomyositisSep 30thAstraZenecaNCT06455449
Added 1 new site: Bangalore, India

Added 1 new site: Bangalore, India

Enrollment UpdateCystic FibrosisSep 30thVertex Pharmaceuticals IncorporatedNCT07437105
Target enrollment increased from 128 to 160

Target enrollment increased from 128 to 160

Enrollment UpdateCystic FibrosisSep 30thAssiut UniversityNCT07147803
Target enrollment increased from 60 to 200

Target enrollment increased from 60 to 200

eligibility_changeCystic FibrosisSep 30thAssiut UniversityNCT07147803
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 30thargenxNCT07091630
Added 3 new sites: Rio de Janeiro, Brazil, Pôrto Alegre, Brazil, Ribeirão Preto, Brazil

Added 3 new sites: Rio de Janeiro, Brazil, Pôrto Alegre, Brazil, Ribeirão Preto, Brazil

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thVA Office of Research and DevelopmentNCT07149870
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thMerck Sharp & Dohme LLCNCT05947851
Added 27 new sites: Clermont, Florida, Fort Wayne, Indiana, Bethesda, Maryland and 24 more

Added 27 new sites: Clermont, Florida, Fort Wayne, Indiana, Bethesda, Maryland and 24 more

sites_addedChronic Graft-versus-Host DiseaseSep 30thBeOne MedicinesNCT06846671
Added 14 new sites: San Diego, California, Golden, Colorado, Grand Rapids, Michigan and 11 more

Added 14 new sites: San Diego, California, Golden, Colorado, Grand Rapids, Michigan and 11 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thNational Institute of Allergy and Infectious Diseases (NIAID)NCT07113743
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 30thNanordica Medical OUNCT06667752
Target enrollment decreased from 170 to 136

Target enrollment decreased from 170 to 136

sites_addedChronic Graft-versus-Host DiseaseSep 30thIntegerBioNCT07389044
Added 4 new sites: Hong Kong, Hong Kong, Hong Kong, Hong Kong, Auckland, New Zealand and 1 more

Added 4 new sites: Hong Kong, Hong Kong, Hong Kong, Hong Kong, Auckland, New Zealand and 1 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thIntegerBioNCT07389044
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 30thMagnetic TidesNCT07631078
Target enrollment decreased from 12 to 6

Target enrollment decreased from 12 to 6

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thMagnetic TidesNCT07631078
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thTakedaNCT06722235
Added 12 new sites: Hot Springs, Arkansas, San Diego, California, Indianapolis, Indiana and 9 more

Added 12 new sites: Hot Springs, Arkansas, San Diego, California, Indianapolis, Indiana and 9 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thTakedaNCT06722235
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thZenas BioPharma (USA), LLCNCT07067463
Added 56 new sites: Pheonix, Arizona, West Hollywood, California, Tampa, Florida and 53 more

Added 56 new sites: Pheonix, Arizona, West Hollywood, California, Tampa, Florida and 53 more

sites_addedChronic Graft-versus-Host DiseaseSep 30thXyloCor Therapeutics, Inc.NCT07048808
Added 13 new sites: Birmingham, Alabama, Phoenix, Arizona, Atlanta, Georgia and 10 more

Added 13 new sites: Birmingham, Alabama, Phoenix, Arizona, Atlanta, Georgia and 10 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thJohns Hopkins UniversityNCT07059091
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thAltesa Biosciences, Inc.NCT07610395
Added 31 new sites: Mobile, Alabama, Inglewood, California, Bradenton, Florida and 28 more

Added 31 new sites: Mobile, Alabama, Inglewood, California, Bradenton, Florida and 28 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thAltesa Biosciences, Inc.NCT07610395
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 30thAstraZenecaNCT07520162
Added 4 new sites: Guangzhou, China, Guangzhou, China, Hangzhou, China and 1 more

Added 4 new sites: Guangzhou, China, Guangzhou, China, Hangzhou, China and 1 more

sites_addedChronic Graft-versus-Host DiseaseSep 30thJanssen Research & Development, LLCNCT06788509
Added 10 new sites: Macquarie University, Australia, Melbourne, Australia, Randwick, Australia and 7 more

Added 10 new sites: Macquarie University, Australia, Melbourne, Australia, Randwick, Australia and 7 more

sites_addedChronic Graft-versus-Host DiseaseSep 30thAstraZenecaNCT06749457
Added 1 new site: Las Vegas, Nevada

Added 1 new site: Las Vegas, Nevada

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thAstraZenecaNCT06749457
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseSep 30thNational Institute of Allergy and Infectious Diseases (NIAID)NCT06253507
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 30thUniversity of UtahNCT05607381
Target enrollment increased from 150 to 188

Target enrollment increased from 150 to 188

sites_addedChronic Graft-versus-Host DiseaseSep 30thOttawa Hospital Research InstituteNCT06392776
Added 3 new sites: Kingston, Canada, Toronto, Canada, Québec, Canada

Added 3 new sites: Kingston, Canada, Toronto, Canada, Québec, Canada

sites_addedChronic Graft-versus-Host DiseaseSep 30thWindward BioNCT07646587
Added 17 new sites: Los Angeles, California, Medford, Oregon, DuBois, Pennsylvania and 14 more

Added 17 new sites: Los Angeles, California, Medford, Oregon, DuBois, Pennsylvania and 14 more

sites_addedCholangiocarcinomaSep 30thAstraZenecaNCT07221253
Added 6 new sites: Miami, Florida, Mineola, New York, Oklahoma City, Oklahoma and 3 more

Added 6 new sites: Miami, Florida, Mineola, New York, Oklahoma City, Oklahoma and 3 more

Enrollment UpdateCholangiocarcinomaSep 30thMassachusetts General HospitalNCT06302621
Target enrollment decreased from 70 to 32

Target enrollment decreased from 70 to 32

sites_addedBecker Muscular DystrophySep 29thAvidity Biosciences, Inc.NCT07587242
Added 2 new sites: Milan, Italy, Leiden, Netherlands

Added 2 new sites: Milan, Italy, Leiden, Netherlands

sites_addedBecker Muscular DystrophySep 29thAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Nantes, France

Added 1 new site: Nantes, France

sites_addedBecker Muscular DystrophySep 29thSatellos Bioscience, Inc.NCT06867107
Added 3 new sites: Los Angeles, California, Columbus, Ohio, Memphis, Tennessee

Added 3 new sites: Los Angeles, California, Columbus, Ohio, Memphis, Tennessee

Enrollment UpdateBecker Muscular DystrophySep 29thSatellos Bioscience, Inc.NCT06867107
Target enrollment increased from 10 to 30

Target enrollment increased from 10 to 30

eligibility_changeBecker Muscular DystrophySep 29thSatellos Bioscience, Inc.NCT06867107
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Sep 29thNovo Nordisk A/SNCT07207811
Added 2 new sites: Allentown, Pennsylvania, Buenos Aires, Argentina

Added 2 new sites: Allentown, Pennsylvania, Buenos Aires, Argentina

eligibility_changeATTR Amyloidosis (Transthyretin Amyloidosis)Sep 29thBayerNCT07298044
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeAplastic AnemiaSep 29thNational Heart, Lung, and Blood Institute (NHLBI)NCT05012111
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAmyotrophic Lateral SclerosisSep 29thEli Lilly and CompanyNCT07571200
Added 1 new site: Calgary, Canada

Added 1 new site: Calgary, Canada

sites_addedAmyotrophic Lateral SclerosisSep 29thEli Lilly and CompanyNCT07571174
Added 1 new site: Calgary, Canada

Added 1 new site: Calgary, Canada

sites_addedAlpha-1 Antitrypsin DeficiencySep 29thTessera Therapeutics, Inc.NCT07227207
Added 1 new site: Jacksonville, Florida

Added 1 new site: Jacksonville, Florida

eligibility_changeAlpha-1 Antitrypsin DeficiencySep 29thWeill Medical College of Cornell UniversityNCT06996756
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAchondroplasiaSep 29thBioMarin PharmaceuticalNCT07441876
Added 4 new sites: Dallas, Texas, Québec, Canada, Milan, Italy and 1 more

Added 4 new sites: Dallas, Texas, Québec, Canada, Milan, Italy and 1 more

sites_addedAchondroplasiaSep 29thSYSNAVNCT07388966
Added 3 new sites: Liège, Belgium, Liège, Belgium, London, United Kingdom

Added 3 new sites: Liège, Belgium, Liège, Belgium, London, United Kingdom

Enrollment UpdateAchondroplasiaSep 29thSYSNAVNCT07388966
Target enrollment increased from 40 to 140

Target enrollment increased from 40 to 140

eligibility_changeAchondroplasiaSep 29thSYSNAVNCT07388966
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedX-Linked HypophosphatemiaSep 28thKyowa Kirin Co., Ltd.NCT06525636
Added 1 new site: Oakville, Canada

Added 1 new site: Oakville, Canada

Enrollment UpdateX-Linked HypophosphatemiaSep 28thKyowa Kirin Co., Ltd.NCT06525636
Target enrollment increased from 24 to 39

Target enrollment increased from 24 to 39

eligibility_changeX-Linked HypophosphatemiaSep 28thKyowa Kirin Co., Ltd.NCT06525636
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeWild-Type ATTR Cardiac AmyloidosisSep 28thBayerNCT07298044
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedThyroid Eye DiseaseSep 27thargenxNCT07596849
Added 12 new sites: Pazardzhik, Bulgaria, Varna, Bulgaria, Varna, Bulgaria and 9 more

Added 12 new sites: Pazardzhik, Bulgaria, Varna, Bulgaria, Varna, Bulgaria and 9 more

sites_addedThyroid Eye DiseaseSep 27thargenxNCT07570316
Added 3 new sites: Jacksonville, Florida, Miami, Florida, Albany, New York

Added 3 new sites: Jacksonville, Florida, Miami, Florida, Albany, New York

sites_addedTay-Sachs DiseaseSep 27thAzafaros B.V.NCT07082543
Added 1 new site: Paris, France

Added 1 new site: Paris, France

sites_addedTay-Sachs DiseaseSep 27thAzafaros B.V.NCT07054515
Added 1 new site: Paris, France

Added 1 new site: Paris, France

sites_addedSystemic SclerosisSep 27thargenxNCT06655155
Added 1 new site: Lille, France

Added 1 new site: Lille, France

sites_addedSystemic MastocytosisSep 27thBlueprint Medicines CorporationNCT04910685
Added 1 new site: Santiago, Chile

Added 1 new site: Santiago, Chile

sites_addedSystemic Juvenile Idiopathic ArthritisSep 27thSanofiNCT02991469
Added 7 new sites: Athens, Greece, Budapest, Hungary, Mérida, Mexico and 4 more

Added 7 new sites: Athens, Greece, Budapest, Hungary, Mérida, Mexico and 4 more

eligibility_changeSystemic Juvenile Idiopathic ArthritisSep 27thNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT03510442
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedSickle Cell DiseaseSep 27thDisc Medicine, IncNCT07187973
Added 1 new site: Pittsburgh, Pennsylvania

Added 1 new site: Pittsburgh, Pennsylvania

sites_addedRetinitis PigmentosaSep 27thOctant, Inc.NCT07408232
Added 1 new site: Portland, Oregon

Added 1 new site: Portland, Oregon

sites_addedPulmonary Arterial HypertensionSep 26thForesee Pharmaceuticals Co., Ltd.NCT06475781
Added 2 new sites: Banja Luka, Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina

Added 2 new sites: Banja Luka, Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina

Enrollment UpdatePulmonary Arterial HypertensionSep 26thChinese Pulmonary Vascular Disease Research GroupNCT04206852
Target enrollment increased from 200 to 1000

Target enrollment increased from 200 to 1000

sites_addedPulmonary Arterial HypertensionSep 26thRegeneron PharmaceuticalsNCT07318597
Added 2 new sites: Brisbane, Australia, London, United Kingdom

Added 2 new sites: Brisbane, Australia, London, United Kingdom

sites_addedPulmonary Arterial HypertensionSep 26thMerck Sharp & Dohme LLCNCT07218029
Added 1 new site: Atlanta, Georgia

Added 1 new site: Atlanta, Georgia

sites_addedPolycythemia VeraSep 26thNovartis PharmaceuticalsNCT07357727
Added 20 new sites: Fort Myers, Florida, Miami, Florida, St. Petersburg, Florida and 17 more

Added 20 new sites: Fort Myers, Florida, Miami, Florida, St. Petersburg, Florida and 17 more

sites_addedPhelan-McDermid SyndromeSep 26thNeuren Pharmaceuticals LimitedNCT07593391
Added 3 new sites: Birmingham, Alabama, Brookline, Massachusetts, New York, New York

Added 3 new sites: Birmingham, Alabama, Brookline, Massachusetts, New York, New York

sites_addedPhelan-McDermid SyndromeSep 26thNeuren Pharmaceuticals LimitedNCT07281079
Added 2 new sites: Washington D.C., District of Columbia, Atlanta, Georgia

Added 2 new sites: Washington D.C., District of Columbia, Atlanta, Georgia

sites_addedOsteogenesis ImperfectaSep 26thAngitia Biopharmaceuticals Guangzhou LimitedNCT07557446
Added 1 new site: Changsha, China

Added 1 new site: Changsha, China

sites_removedNoonan SyndromeSep 26thBioMarin PharmaceuticalNCT06668805
Reduced from 41 to 38 sites

Reduced from 41 to 38 sites

sites_addedNiemann-Pick Disease Type CSep 26thAzafaros B.V.NCT07082543
Added 1 new site: Paris, France

Added 1 new site: Paris, France

sites_addedNiemann-Pick Disease Type CSep 26thAzafaros B.V.NCT07054515
Added 1 new site: Paris, France

Added 1 new site: Paris, France

sites_addedNiemann-Pick DiseaseSep 26thAzafaros B.V.NCT07054515
Added 1 new site: Paris, France

Added 1 new site: Paris, France

eligibility_changeNeuromyelitis OpticaSep 26thTongji HospitalNCT06620809
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeNeurofibromatosis Type 1Sep 26thNational Cancer Institute (NCI)NCT00924196
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyotonic DystrophySep 25thDyne TherapeuticsNCT07486934
Added 2 new sites: Rochester, New York, Göttingen, Germany

Added 2 new sites: Rochester, New York, Göttingen, Germany

sites_addedMyelofibrosisSep 25thNovartis PharmaceuticalsNCT07357727
Added 6 new sites: Fort Myers, Florida, Dallas, Texas, Ostrava, Czechia and 3 more

Added 6 new sites: Fort Myers, Florida, Dallas, Texas, Ostrava, Czechia and 3 more

sites_addedMyelodysplastic SyndromesSep 25thJanssen Research & Development, LLCNCT06788509
Added 2 new sites: Melbourne, Australia, Athens, Greece

Added 2 new sites: Melbourne, Australia, Athens, Greece

sites_addedMyasthenia GravisSep 25thJanssen Research & Development, LLCNCT07217587
Added 2 new sites: Foxborough, Massachusetts, Austin, Texas

Added 2 new sites: Foxborough, Massachusetts, Austin, Texas

sites_addedMyasthenia GravisSep 25thUCB Biopharma SRLNCT07463521
Added 3 new sites: Alicante, Spain, Barcelona, Spain, Madrid, Spain

Added 3 new sites: Alicante, Spain, Barcelona, Spain, Madrid, Spain

sites_addedMyasthenia GravisSep 25thDianthus TherapeuticsNCT07647510
Added 1 new site: Pasadena, California

Added 1 new site: Pasadena, California

sites_addedMesotheliomaSep 25thIDEAYA BiosciencesNCT07277413
Added 1 new site: Goodyear, Arizona

Added 1 new site: Goodyear, Arizona

sites_addedMerkel Cell CarcinomaSep 25thWeill Medical College of Cornell UniversityNCT05583708
Added 1 new site: Duarte, California

Added 1 new site: Duarte, California

sites_addedNarcolepsy Type 1Sep 25thTakedaNCT07646678
Added 11 new sites: Chula Vista, California, Colorado Springs, Colorado, Winter Park, Florida and 8 more

Added 11 new sites: Chula Vista, California, Colorado Springs, Colorado, Winter Park, Florida and 8 more

sites_addedMyotonic DystrophySep 25thSanofiNCT06844214
Added 1 new site: Philadelphia, Pennsylvania

Added 1 new site: Philadelphia, Pennsylvania

sites_addedMyotonic DystrophySep 25thAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Nantes, France

Added 1 new site: Nantes, France

eligibility_changeMyelofibrosisSep 25thPrelude Therapeutics IncorporatedNCT07469891
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelofibrosisSep 25thSumitomo Pharma America, Inc.NCT04176198
Added 1 new site: Tokyo, Japan

Added 1 new site: Tokyo, Japan

sites_addedMyelofibrosisSep 25thNovartis PharmaceuticalsNCT07357727
Added 15 new sites: Miami, Florida, St. Petersburg, Florida, Sankt Pölten, Austria and 12 more

Added 15 new sites: Miami, Florida, St. Petersburg, Florida, Sankt Pölten, Austria and 12 more

sites_addedMyelodysplastic SyndromesSep 25thTakedaNCT07422480
Added 13 new sites: New Haven, Connecticut, Monroe, Louisiana, Shreveport, Louisiana and 10 more

Added 13 new sites: New Haven, Connecticut, Monroe, Louisiana, Shreveport, Louisiana and 10 more

sites_addedMyelodysplastic SyndromesSep 25thNational Cancer Institute (NCI)NCT05564390
Added 1 new site: Harvey, Illinois

Added 1 new site: Harvey, Illinois

sites_addedMyasthenia GravisSep 25thTG Therapeutics, Inc.NCT07673744
Added 1 new site: Greenville, South Carolina

Added 1 new site: Greenville, South Carolina

sites_addedMyasthenia GravisSep 25thargenxNCT07294170
Added 6 new sites: Las Vegas, Nevada, Chapel Hill, North Carolina, Cincinnati, Ohio and 3 more

Added 6 new sites: Las Vegas, Nevada, Chapel Hill, North Carolina, Cincinnati, Ohio and 3 more

sites_addedMyasthenia GravisSep 25thargenxNCT07673627
Added 1 new site: Austin, Texas

Added 1 new site: Austin, Texas

sites_addedMyasthenia GravisSep 25thargenxNCT07284420
Added 6 new sites: Las Vegas, Nevada, Chapel Hill, North Carolina, Cincinnati, Ohio and 3 more

Added 6 new sites: Las Vegas, Nevada, Chapel Hill, North Carolina, Cincinnati, Ohio and 3 more

sites_addedMyasthenia GravisSep 25thargenxNCT06392386
Added 1 new site: Melbourne, Australia

Added 1 new site: Melbourne, Australia

eligibility_changeMultiple SclerosisSep 25thHoffmann-La RocheNCT04544449
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisSep 25thZenas BioPharma (USA), LLCNCT07067463
Added 2 new sites: Kansas City, Kansas, Katowice, Poland

Added 2 new sites: Kansas City, Kansas, Katowice, Poland

sites_addedMultiple SclerosisSep 25thTG Therapeutics, Inc.NCT06433752
Added 2 new sites: Lincoln, Nebraska, London, United Kingdom

Added 2 new sites: Lincoln, Nebraska, London, United Kingdom

sites_addedMultiple SclerosisSep 25thTG Therapeutics, Inc.NCT07220252
Added 1 new site: Warsaw, Poland

Added 1 new site: Warsaw, Poland

sites_addedMultiple SclerosisSep 25thTr1X, Inc.NCT07477639
Added 6 new sites: La Jolla, California, Rochester, Minnesota, New York, New York and 3 more

Added 6 new sites: La Jolla, California, Rochester, Minnesota, New York, New York and 3 more

sites_addedMultiple SclerosisSep 25thZenas BioPharma (USA), LLCNCT07299019
Added 2 new sites: Tampa, Florida, Poznan, Poland

Added 2 new sites: Tampa, Florida, Poznan, Poland

sites_removedMultiple SclerosisSep 25thHoffmann-La RocheNCT04586010
Reduced from 160 to 158 sites

Reduced from 160 to 158 sites

eligibility_changeMultiple SclerosisSep 25thHoffmann-La RocheNCT04586010
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMixed Connective Tissue DiseaseSep 25thParadigm HealthNCT06605404
Added 45 new sites: Birmingham, Alabama, Bullhead City, Arizona, Casa Grande, Arizona and 42 more

Added 45 new sites: Birmingham, Alabama, Bullhead City, Arizona, Casa Grande, Arizona and 42 more

sites_addedMixed Connective Tissue DiseaseSep 25thNational Cancer Institute (NCI)NCT04616560
Added 1 new site: Portland, Oregon

Added 1 new site: Portland, Oregon

eligibility_changeMesotheliomaSep 25thMemorial Sloan Kettering Cancer CenterNCT06057935
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMesotheliomaSep 25thIDEAYA BiosciencesNCT07277413
Added 3 new sites: Phoenix, Arizona, Jacksonville, Florida, Rochester, Minnesota

Added 3 new sites: Phoenix, Arizona, Jacksonville, Florida, Rochester, Minnesota

sites_addedMerkel Cell CarcinomaSep 25thUniversity of ArizonaNCT06814496
Added 1 new site: Gilbert, Arizona

Added 1 new site: Gilbert, Arizona

sites_addedMerkel Cell CarcinomaSep 25thNovartis PharmaceuticalsNCT07006727
Added 1 new site: Chuo Ku, Japan

Added 1 new site: Chuo Ku, Japan

sites_addedMembranous NephropathySep 25thVertex Pharmaceuticals IncorporatedNCT07204275
Added 1 new site: Indianapolis, Indiana

Added 1 new site: Indianapolis, Indiana

sites_addedMedullary Thyroid CancerSep 25thUniversity of ArizonaNCT06814496
Added 1 new site: Gilbert, Arizona

Added 1 new site: Gilbert, Arizona

sites_addedMedullary Thyroid CancerSep 25thNovartis PharmaceuticalsNCT07006727
Added 1 new site: Chuo Ku, Japan

Added 1 new site: Chuo Ku, Japan

sites_addedMastocytosisSep 25thBlueprint Medicines CorporationNCT04910685
Added 1 new site: Santiago, Chile

Added 1 new site: Santiago, Chile

sites_addedIdiopathic Pulmonary FibrosisSep 24thContineum TherapeuticsNCT07284459
Added 3 new sites: Nice, France, Kaohsiung City, Taiwan, Taipei, Taiwan

Added 3 new sites: Nice, France, Kaohsiung City, Taiwan, Taipei, Taiwan

sites_addedHodgkin LymphomaSep 24thMerck Sharp & Dohme LLCNCT07570173
Added 2 new sites: Odense C, Denmark, Bergamo, Italy

Added 2 new sites: Odense C, Denmark, Bergamo, Italy

sites_addedHodgkin LymphomaSep 24thMemorial Sloan Kettering Cancer CenterNCT07223021
Added 1 new site: Utrecht, Netherlands

Added 1 new site: Utrecht, Netherlands

Enrollment UpdateHodgkin LymphomaSep 24thMemorial Sloan Kettering Cancer CenterNCT07223021
Target enrollment increased from 65 to 130

Target enrollment increased from 65 to 130

sites_addedHodgkin LymphomaSep 24thAutolus LimitedNCT03628612
Added 1 new site: Barcelona, Spain

Added 1 new site: Barcelona, Spain

sites_addedHodgkin LymphomaSep 24thMerck Sharp & Dohme LLCNCT07519772
Added 1 new site: CABA, Argentina

Added 1 new site: CABA, Argentina

eligibility_changeHodgkin LymphomaSep 24thUniversity of PennsylvaniaNCT07343934
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 24thMerck Sharp & Dohme LLCNCT06890884
Added 4 new sites: Bruges, Belgium, Ulm, Germany, Dublin, Ireland and 1 more

Added 4 new sites: Bruges, Belgium, Ulm, Germany, Dublin, Ireland and 1 more

sites_addedHodgkin LymphomaSep 24thNational Cancer Institute (NCI)NCT05675410
Added 1 new site: Williamsville, New York

Added 1 new site: Williamsville, New York

sites_removedHodgkin LymphomaSep 24thAcerta Pharma BVNCT02180711
Reduced from 32 to 29 sites

Reduced from 32 to 29 sites

sites_addedHodgkin LymphomaSep 24thAlliance for Clinical Trials in OncologyNCT07215910
Added 24 new sites: Bakersfield, California, Coral Gables, Florida, Coral Springs, Florida and 21 more

Added 24 new sites: Bakersfield, California, Coral Gables, Florida, Coral Springs, Florida and 21 more

eligibility_changeImmune ThrombocytopeniaSep 24thTakedaNCT06722235
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedImmune ThrombocytopeniaSep 24thargenxNCT07194850
Added 1 new site: Osaka, Japan

Added 1 new site: Osaka, Japan

sites_removedImmune ThrombocytopeniaSep 24thEli Lilly and CompanyNCT06721013
Reduced from 45 to 43 sites

Reduced from 45 to 43 sites

sites_addedIgG4-Related DiseaseSep 24thSanofiNCT07190196
Added 19 new sites: Sacramento, California, Detroit, Michigan, New York, New York and 16 more

Added 19 new sites: Sacramento, California, Detroit, Michigan, New York, New York and 16 more

sites_addedIgA NephropathySep 24thSitala Bio LTDNCT07606352
Added 5 new sites: Newcastle, Australia, Penrith, Australia, Sydney, Australia and 2 more

Added 5 new sites: Newcastle, Australia, Penrith, Australia, Sydney, Australia and 2 more

sites_addedIgA NephropathySep 24thNovartis PharmaceuticalsNCT07498335
Added 3 new sites: Kanazawa, Japan, Barcelona, Spain, Taipei, Taiwan

Added 3 new sites: Kanazawa, Japan, Barcelona, Spain, Taipei, Taiwan

sites_addedIdiopathic Pulmonary FibrosisSep 24thChiesi Farmaceutici S.p.A.NCT07516951
Added 1 new site: Hannibal, Missouri

Added 1 new site: Hannibal, Missouri

sites_addedIdiopathic Pulmonary FibrosisSep 24thAstraZenecaNCT07652658
Added 4 new sites: Camperdown, Australia, Amsterdam, Netherlands, Heerlen, Netherlands and 1 more

Added 4 new sites: Camperdown, Australia, Amsterdam, Netherlands, Heerlen, Netherlands and 1 more

sites_addedIdiopathic Pulmonary FibrosisSep 24thContineum TherapeuticsNCT07284459
Added 3 new sites: Lima, Peru, San Miguel, Peru, Bydgoszcz, Poland

Added 3 new sites: Lima, Peru, San Miguel, Peru, Bydgoszcz, Poland

sites_addedHuntington DiseaseSep 24thNovartis PharmaceuticalsNCT07326709
Added 37 new sites: San Francisco, California, Miami, Florida, Chicago, Illinois and 34 more

Added 37 new sites: San Francisco, California, Miami, Florida, Chicago, Illinois and 34 more

sites_addedHuntington DiseaseSep 24thSkyhawk Therapeutics, Inc.NCT07378644
Added 2 new sites: Taufkirchen, Germany, Madrid, Spain

Added 2 new sites: Taufkirchen, Germany, Madrid, Spain

sites_addedHodgkin LymphomaSep 24thMerck Sharp & Dohme LLCNCT07634471
Added 6 new sites: Duarte, California, Lexington, Kentucky, Hackensack, New Jersey and 3 more

Added 6 new sites: Duarte, California, Lexington, Kentucky, Hackensack, New Jersey and 3 more

sites_addedHodgkin LymphomaSep 24thNational Cancer Institute (NCI)NCT06649812
Added 17 new sites: Crown Point, Indiana, Dyer, Indiana, Hobart, Indiana and 14 more

Added 17 new sites: Crown Point, Indiana, Dyer, Indiana, Hobart, Indiana and 14 more

Enrollment UpdateHodgkin LymphomaSep 24thBioInvent International ABNCT04752826
Target enrollment increased from 176 to 250

Target enrollment increased from 176 to 250

eligibility_changeHodgkin LymphomaSep 24thBioInvent International ABNCT04752826
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 24thNovartis PharmaceuticalsNCT06784752
Added 3 new sites: Orlando, Florida, Atlanta, Georgia, Glasgow, United Kingdom

Added 3 new sites: Orlando, Florida, Atlanta, Georgia, Glasgow, United Kingdom

sites_addedHodgkin LymphomaSep 24thAstraZenecaNCT06137144
Added 2 new sites: São Paulo, Brazil, São Paulo, Brazil

Added 2 new sites: São Paulo, Brazil, São Paulo, Brazil

eligibility_changeHodgkin LymphomaSep 24thAstraZenecaNCT06137144
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHodgkin LymphomaSep 24thMemorial Sloan Kettering Cancer CenterNCT06756308
Target enrollment decreased from 25 to 2

Target enrollment decreased from 25 to 2

sites_addedHodgkin LymphomaSep 24thArvinas Inc.NCT06393738
Added 4 new sites: Miami, Florida, Charlottesville, Virginia, East Melbourne, Australia and 1 more

Added 4 new sites: Miami, Florida, Charlottesville, Virginia, East Melbourne, Australia and 1 more

Enrollment UpdateHodgkin LymphomaSep 24thArvinas Inc.NCT06393738
Target enrollment increased from 255 to 329

Target enrollment increased from 255 to 329

eligibility_changeHodgkin LymphomaSep 24thArvinas Inc.NCT06393738
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 24thCanadian Cancer Trials GroupNCT07341191
Added 1 new site: Calgary, Canada

Added 1 new site: Calgary, Canada

eligibility_changeHereditary AngioedemaSep 24thPharvaris Netherlands B.V.NCT06679881
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHereditary AngioedemaSep 24thPharvaris Netherlands B.V.NCT07266805
Target enrollment increased from 32 to 48

Target enrollment increased from 32 to 48

eligibility_changeHereditary AngioedemaSep 24thPharvaris Netherlands B.V.NCT07266805
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHemophilia ASep 24thSanofiNCT06145373
Added 2 new sites: Flowood, Mississippi, Taipei, Taiwan

Added 2 new sites: Flowood, Mississippi, Taipei, Taiwan

sites_addedHemophilia ASep 24thHoffmann-La RocheNCT07416526
Added 5 new sites: Beijing, China, Lille, France, Zurich, Switzerland and 2 more

Added 5 new sites: Beijing, China, Lille, France, Zurich, Switzerland and 2 more

sites_addedFocal Segmental GlomerulosclerosisSep 23rdSanofiNCT06500702
Added 26 new sites: Birmingham, Alabama, Orange, California, San Francisco, California and 23 more

Added 26 new sites: Birmingham, Alabama, Orange, California, San Francisco, California and 23 more

sites_addedEssential ThrombocythemiaSep 23rdNovartis PharmaceuticalsNCT07357727
Added 12 new sites: Miami, Florida, St. Petersburg, Florida, Florianópolis, Brazil and 9 more

Added 12 new sites: Miami, Florida, St. Petersburg, Florida, Florianópolis, Brazil and 9 more

sites_addedGraves’ DiseaseSep 23rdBiohaven Therapeutics Ltd.NCT07661056
Added 6 new sites: Hollywood, Florida, Baton Rouge, Louisiana, Kansas City, Missouri and 3 more

Added 6 new sites: Hollywood, Florida, Baton Rouge, Louisiana, Kansas City, Missouri and 3 more

sites_addedGraves’ DiseaseSep 23rdargenxNCT07570316
Added 4 new sites: Jacksonville, Florida, Miami, Florida, Kansas City, Missouri and 1 more

Added 4 new sites: Jacksonville, Florida, Miami, Florida, Kansas City, Missouri and 1 more

sites_addedGraves’ DiseaseSep 23rdargenxNCT07596849
Added 17 new sites: Pazardzhik, Bulgaria, Sliven, Bulgaria, Varna, Bulgaria and 14 more

Added 17 new sites: Pazardzhik, Bulgaria, Sliven, Bulgaria, Varna, Bulgaria and 14 more

sites_addedGranulomatosis with PolyangiitisSep 23rdAstraZenecaNCT07444567
Expanded from 45 to 46 sites

Expanded from 45 to 46 sites

sites_addedGiant Cell ArteritisSep 23rdSanofiNCT07286214
Added 60 new sites: Avondale, Arizona, Phoenix, Arizona, Tucson, Arizona and 57 more

Added 60 new sites: Avondale, Arizona, Phoenix, Arizona, Tucson, Arizona and 57 more

sites_addedGeographic AtrophySep 23rdRegeneron PharmaceuticalsNCT06541704
Added 1 new site: Rouen, France

Added 1 new site: Rouen, France

sites_addedGeographic AtrophySep 23rdSanofiNCT07215234
Added 14 new sites: Beverly Hills, California, Encino, California, Sacramento, California and 11 more

Added 14 new sites: Beverly Hills, California, Encino, California, Sacramento, California and 11 more

sites_removedGeographic AtrophySep 23rdAstellas Pharma Global Development, Inc.NCT06779773
Reduced from 65 to 58 sites

Reduced from 65 to 58 sites

sites_addedFragile X SyndromeSep 23rdMirum Pharmaceuticals, Inc.NCT07209462
Added 1 new site: Barcelona, Spain

Added 1 new site: Barcelona, Spain

sites_removedFocal Segmental GlomerulosclerosisSep 23rdBoehringer IngelheimNCT07220083
Reduced from 309 to 307 sites

Reduced from 309 to 307 sites

eligibility_changeFanconi AnemiaSep 23rdNational Heart, Lung, and Blood Institute (NHLBI)NCT03206086
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeFanconi AnemiaSep 23rdVA Office of Research and DevelopmentNCT04038502
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedFanconi AnemiaSep 23rdNovartis PharmaceuticalsNCT06910813
Added 4 new sites: Phoenix, Arizona, San Diego, California, Stanford, California and 1 more

Added 4 new sites: Phoenix, Arizona, San Diego, California, Stanford, California and 1 more

Enrollment UpdateFabry DiseaseSep 23rdGeneral University Hospital, PragueNCT07495410
Target enrollment increased from 15 to 50

Target enrollment increased from 15 to 50

eligibility_changeFabry DiseaseSep 23rdGeneral University Hospital, PragueNCT07495410
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateEssential ThrombocythemiaSep 23rdAjax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06343805
Target enrollment increased from 76 to 256

Target enrollment increased from 76 to 256

eligibility_changeEssential ThrombocythemiaSep 23rdAjax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06343805
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedEssential ThrombocythemiaSep 23rdNovartis PharmaceuticalsNCT07357727
Added 4 new sites: Jinan, China, Padova, Italy, Bunkyo Ku, Japan and 1 more

Added 4 new sites: Jinan, China, Padova, Italy, Bunkyo Ku, Japan and 1 more

eligibility_changeEssential ThrombocythemiaSep 23rdPrelude Therapeutics IncorporatedNCT07469891
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedEosinophilic Granulomatosis with PolyangiitisSep 23rdAstraZenecaNCT07444567
Expanded from 45 to 46 sites

Expanded from 45 to 46 sites

sites_addedEosinophilic EsophagitisSep 23rdSanofiNCT06695897
Added 14 new sites: Aschaffenburg, Germany, Augsburg, Germany, Erlangen, Germany and 11 more

Added 14 new sites: Aschaffenburg, Germany, Augsburg, Germany, Erlangen, Germany and 11 more

sites_addedDuchenne Muscular DystrophySep 22ndAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Nantes, France

Added 1 new site: Nantes, France

Enrollment UpdateCystic FibrosisSep 22ndChildren's Hospital Medical Center, CincinnatiNCT05517655
Target enrollment decreased from 44 to 19

Target enrollment decreased from 44 to 19

sites_addedCystic FibrosisSep 22ndAnagram Therapeutics, Inc.NCT07450547
Added 1 new site: Minneapolis, Minnesota

Added 1 new site: Minneapolis, Minnesota

sites_removedChronic Inflammatory Demyelinating PolyneuropathySep 22ndSanofiNCT06290141
Reduced from 135 to 133 sites

Reduced from 135 to 133 sites

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 22ndargenxNCT06920004
Added 6 new sites: Nicholasville, Kentucky, São Paulo, Brazil, Calgary, Canada and 3 more

Added 6 new sites: Nicholasville, Kentucky, São Paulo, Brazil, Calgary, Canada and 3 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndSanofiNCT06290128
Added 7 new sites: Miami Lakes, Florida, New York, New York, Belo Horizonte, Brazil and 4 more

Added 7 new sites: Miami Lakes, Florida, New York, New York, Belo Horizonte, Brazil and 4 more

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndSanofiNCT06290128
Target enrollment decreased from 140 to 109

Target enrollment decreased from 140 to 109

eligibility_changeChronic Graft-versus-Host DiseaseSep 22ndUniversity GhentNCT06892977
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 22ndTr1X, Inc.NCT07477639
Added 6 new sites: La Jolla, California, Rochester, Minnesota, New York, New York and 3 more

Added 6 new sites: La Jolla, California, Rochester, Minnesota, New York, New York and 3 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndGigaGen, Inc.NCT07024641
Added 2 new sites: Songpa-dong, South Korea, Sanmin, Taiwan

Added 2 new sites: Songpa-dong, South Korea, Sanmin, Taiwan

sites_addedChronic Graft-versus-Host DiseaseSep 22ndargenxNCT07194850
Added 1 new site: Osaka, Japan

Added 1 new site: Osaka, Japan

sites_removedChronic Graft-versus-Host DiseaseSep 22ndGuangdong Provincial People's HospitalNCT04381143
Reduced from 139 to 127 sites

Reduced from 139 to 127 sites

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndGuangdong Provincial People's HospitalNCT04381143
Target enrollment increased from 9000 to 9082

Target enrollment increased from 9000 to 9082

sites_addedChronic Graft-versus-Host DiseaseSep 22ndNational Cancer Institute (NCI)NCT04269902
Added 1 new site: Novi, Michigan

Added 1 new site: Novi, Michigan

sites_addedChronic Graft-versus-Host DiseaseSep 22ndVironexis Biotherapeutics Inc.NCT06533579
Added 2 new sites: Jacksonville, Florida, Rochester, Minnesota

Added 2 new sites: Jacksonville, Florida, Rochester, Minnesota

sites_addedChronic Graft-versus-Host DiseaseSep 22ndPulmonx CorporationNCT06035120
Added 2 new sites: Loveland, Colorado, Lexington, Kentucky

Added 2 new sites: Loveland, Colorado, Lexington, Kentucky

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndLG ChemNCT06206135
Target enrollment increased from 100 to 172

Target enrollment increased from 100 to 172

eligibility_changeChronic Graft-versus-Host DiseaseSep 22ndAstraZenecaNCT06087835
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedChronic Graft-versus-Host DiseaseSep 22ndBayerNCT05457283
Reduced from 179 to 151 sites

Reduced from 179 to 151 sites

sites_addedCholangiocarcinomaSep 22ndAstellas Pharma Global Development, Inc.NCT07488676
Added 5 new sites: Miami, Florida, Detroit, Michigan, New Brunswick, New Jersey and 2 more

Added 5 new sites: Miami, Florida, Detroit, Michigan, New Brunswick, New Jersey and 2 more

sites_addedDuchenne Muscular DystrophySep 22ndSarepta Therapeutics, Inc.NCT04626674
Added 5 new sites: La Jolla, California, Los Angeles, California, Gainesville, Florida and 2 more

Added 5 new sites: La Jolla, California, Los Angeles, California, Gainesville, Florida and 2 more

eligibility_changeDuchenne Muscular DystrophySep 22ndSarepta Therapeutics, Inc.NCT04626674
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDuchenne Muscular DystrophySep 22ndNS Pharma, Inc.NCT05996003
Added 5 new sites: Boston, Massachusetts, New York, New York, South Brisbane, Australia and 2 more

Added 5 new sites: Boston, Massachusetts, New York, New York, South Brisbane, Australia and 2 more

sites_addedDuchenne Muscular DystrophySep 22ndAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Genova, Italy

Added 1 new site: Genova, Italy

sites_addedDuchenne Muscular DystrophySep 22ndEdgewise Therapeutics, Inc.NCT06066580
Added 18 new sites: Melbourne, Australia, Ghent, Belgium, Leuven, Belgium and 15 more

Added 18 new sites: Melbourne, Australia, Ghent, Belgium, Leuven, Belgium and 15 more

eligibility_changeDuchenne Muscular DystrophySep 22ndEdgewise Therapeutics, Inc.NCT06066580
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDuchenne Muscular DystrophySep 22ndSatellos Bioscience, Inc.NCT06867107
Added 3 new sites: Los Angeles, California, Columbus, Ohio, Memphis, Tennessee

Added 3 new sites: Los Angeles, California, Columbus, Ohio, Memphis, Tennessee

Enrollment UpdateDuchenne Muscular DystrophySep 22ndSatellos Bioscience, Inc.NCT06867107
Target enrollment increased from 10 to 30

Target enrollment increased from 10 to 30

eligibility_changeDuchenne Muscular DystrophySep 22ndSatellos Bioscience, Inc.NCT06867107
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDravet SyndromeSep 22ndLongboard PharmaceuticalsNCT06908226
Added 53 new sites: Los Angeles, California, Palo Alto, California, Aurora, Colorado and 50 more

Added 53 new sites: Los Angeles, California, Palo Alto, California, Aurora, Colorado and 50 more

sites_addedDravet SyndromeSep 22ndLongboard PharmaceuticalsNCT06660394
Added 63 new sites: Los Angeles, California, Los Angeles, California, Palo Alto, California and 60 more

Added 63 new sites: Los Angeles, California, Los Angeles, California, Palo Alto, California and 60 more

eligibility_changeDermatomyositisSep 22ndNational Cancer Institute (NCI)NCT03816345
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDermatomyositisSep 22ndUniversity Hospital, LimogesNCT03582800
Added 3 new sites: Paris, France, Rennes, France, Toulouse, France

Added 3 new sites: Paris, France, Rennes, France, Toulouse, France

sites_removedDermatomyositisSep 22ndPfizerNCT05895786
Reduced from 146 to 138 sites

Reduced from 146 to 138 sites

sites_addedCystic FibrosisSep 22ndUCB Biopharma SRLNCT07720375
Added 1 new site: Brandon, Florida

Added 1 new site: Brandon, Florida

eligibility_changeCystic FibrosisSep 22ndUCB Biopharma SRLNCT07720375
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateCystic FibrosisSep 22ndParagonix TechnologiesNCT04930289
Target enrollment increased from 2000 to 3500

Target enrollment increased from 2000 to 3500

eligibility_changeCystic FibrosisSep 22ndVertex Pharmaceuticals IncorporatedNCT07283770
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedCystic FibrosisSep 22ndiSono Health, Inc.NCT07505797
Added 1 new site: Cypress, Texas

Added 1 new site: Cypress, Texas

sites_addedCongenital Adrenal HyperplasiaSep 22ndNeurocrine Switzerland GmbHNCT07536269
Added 1 new site: Aurora, Colorado

Added 1 new site: Aurora, Colorado

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 22ndargenxNCT06920004
Added 6 new sites: Cincinnati, Ohio, Córdoba, Argentina, Liverpool, Australia and 3 more

Added 6 new sites: Cincinnati, Ohio, Córdoba, Argentina, Liverpool, Australia and 3 more

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 22ndSanofiNCT06859099
Added 13 new sites: Scottsdale, Arizona, Brasília, Brazil, São Paulo, Brazil and 10 more

Added 13 new sites: Scottsdale, Arizona, Brasília, Brazil, São Paulo, Brazil and 10 more

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 22ndKedrion S.p.A.NCT06752356
Added 2 new sites: Stamford, Connecticut, Miami, Florida

Added 2 new sites: Stamford, Connecticut, Miami, Florida

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 22ndargenxNCT07091630
Added 4 new sites: Knoxville, Tennessee, Guangzhou, China, Ramat Gan, Israel and 1 more

Added 4 new sites: Knoxville, Tennessee, Guangzhou, China, Ramat Gan, Israel and 1 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndEli Lilly and CompanyNCT06672549
Added 14 new sites: Oxnard, California, Tainan, China, Taipei, China and 11 more

Added 14 new sites: Oxnard, California, Tainan, China, Taipei, China and 11 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndBeOne MedicinesNCT06973187
Added 5 new sites: New York, New York, Belo Horizonte, Brazil, Changchun, China and 2 more

Added 5 new sites: New York, New York, Belo Horizonte, Brazil, Changchun, China and 2 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndBeOne MedicinesNCT07277231
Added 24 new sites: Duarte, California, Orange, California, Aurora, Colorado and 21 more

Added 24 new sites: Duarte, California, Orange, California, Aurora, Colorado and 21 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndSanofiNCT07190222
Added 1 new site: Athens, Greece

Added 1 new site: Athens, Greece

sites_addedChronic Graft-versus-Host DiseaseSep 22ndHuahui HealthNCT07499544
Added 7 new sites: Garden Grove, California, Changchun, China, Kashgar, China and 4 more

Added 7 new sites: Garden Grove, California, Changchun, China, Kashgar, China and 4 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndViz.ai, Inc.NCT07118306
Added 1 new site: Falls Church, Virginia

Added 1 new site: Falls Church, Virginia

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndM.D. Anderson Cancer CenterNCT06840262
Target enrollment increased from 45 to 54

Target enrollment increased from 45 to 54

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT03756870
Target enrollment decreased from 82 to 48

Target enrollment decreased from 82 to 48

sites_addedChronic Graft-versus-Host DiseaseSep 22ndMedtronicNCT07507422
Added 3 new sites: San Diego, California, San Antonio, Texas, Lille, France

Added 3 new sites: San Diego, California, San Antonio, Texas, Lille, France

sites_removedChronic Graft-versus-Host DiseaseSep 22ndAstraZenecaNCT05637112
Reduced from 79 to 74 sites

Reduced from 79 to 74 sites

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndJohn Paul II Hospital, KrakowNCT05508035
Target enrollment decreased from 666 to 488

Target enrollment decreased from 666 to 488

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndiOMEDICO AGNCT05326308
Target enrollment increased from 705 to 845

Target enrollment increased from 705 to 845

sites_addedChronic Graft-versus-Host DiseaseSep 22ndNovartis PharmaceuticalsNCT07225504
Added 47 new sites: Phoenix, Arizona, Aurora, Colorado, Tampa, Florida and 44 more

Added 47 new sites: Phoenix, Arizona, Aurora, Colorado, Tampa, Florida and 44 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 22ndNovartis PharmaceuticalsNCT07225504
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 22ndVifor Fresenius Medical Care Renal PharmaNCT06593392
Added 1 new site: Xi'an, China

Added 1 new site: Xi'an, China

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 22ndNorthwestern UniversityNCT05719714
Target enrollment decreased from 60 to 18

Target enrollment decreased from 60 to 18

sites_addedChronic Graft-versus-Host DiseaseSep 22ndUCB Biopharma SRLNCT07725939
Added 4 new sites: Beijing, China, Chengdu, China, Hangzhou, China and 1 more

Added 4 new sites: Beijing, China, Chengdu, China, Hangzhou, China and 1 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 22ndUniversity of PittsburghNCT07518719
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 22ndThe University of QueenslandNCT03573089
Added 11 new sites: Ubá, Brazil, Winnipeg, Canada, North York, Canada and 8 more

Added 11 new sites: Ubá, Brazil, Winnipeg, Canada, North York, Canada and 8 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 22ndAstraZenecaNCT07024823
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 22ndNovartis PharmaceuticalsNCT07498335
Added 6 new sites: Beijing, China, Kanazawa, Japan, Chiba, Japan and 3 more

Added 6 new sites: Beijing, China, Kanazawa, Japan, Chiba, Japan and 3 more

sites_addedChronic Graft-versus-Host DiseaseSep 22ndMerz Therapeutics GmbHNCT07018713
Added 2 new sites: Rochester, Minnesota, Żory, Poland

Added 2 new sites: Rochester, Minnesota, Żory, Poland

Enrollment UpdateCholangiocarcinomaSep 22ndArvinas Inc.NCT07023731
Target enrollment decreased from 159 to 76

Target enrollment decreased from 159 to 76

sites_addedAlagille SyndromeSep 21stDigestive Care, Inc.NCT07335523
Added 1 new site: Cincinnati, Ohio

Added 1 new site: Cincinnati, Ohio

sites_addedBecker Muscular DystrophySep 21stEdgewise Therapeutics, Inc.NCT06066580
Added 18 new sites: Melbourne, Australia, Ghent, Belgium, Leuven, Belgium and 15 more

Added 18 new sites: Melbourne, Australia, Ghent, Belgium, Leuven, Belgium and 15 more

eligibility_changeBecker Muscular DystrophySep 21stEdgewise Therapeutics, Inc.NCT06066580
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeBecker Muscular DystrophySep 21stWest China HospitalNCT06114056
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedBecker Muscular DystrophySep 21stSarepta Therapeutics, Inc.NCT04626674
Added 5 new sites: La Jolla, California, Los Angeles, California, Gainesville, Florida and 2 more

Added 5 new sites: La Jolla, California, Los Angeles, California, Gainesville, Florida and 2 more

eligibility_changeBecker Muscular DystrophySep 21stSarepta Therapeutics, Inc.NCT04626674
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedBecker Muscular DystrophySep 21stAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Genova, Italy

Added 1 new site: Genova, Italy

sites_addedBecker Muscular DystrophySep 21stNS Pharma, Inc.NCT05996003
Added 5 new sites: Boston, Massachusetts, New York, New York, South Brisbane, Australia and 2 more

Added 5 new sites: Boston, Massachusetts, New York, New York, South Brisbane, Australia and 2 more

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Sep 21stBayerNCT07298044
Added 6 new sites: Ulm, Germany, Greifswald, Germany, Bonn, Germany and 3 more

Added 6 new sites: Ulm, Germany, Greifswald, Germany, Bonn, Germany and 3 more

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Sep 21stAlnylam PharmaceuticalsNCT07052903
Added 12 new sites: Aurora, Colorado, Austin, Texas, Seattle, Washington and 9 more

Added 12 new sites: Aurora, Colorado, Austin, Texas, Seattle, Washington and 9 more

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Sep 21stAlnylam PharmaceuticalsNCT07223203
Added 7 new sites: Rosario, Argentina, Rio de Janeiro, Brazil, Dublin, Ireland and 4 more

Added 7 new sites: Rosario, Argentina, Rio de Janeiro, Brazil, Dublin, Ireland and 4 more

eligibility_changeAplastic AnemiaSep 21stNational Heart, Lung, and Blood Institute (NHLBI)NCT03206086
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeAplastic AnemiaSep 21stNational Heart, Lung, and Blood Institute (NHLBI)NCT03173937
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAmyotrophic Lateral SclerosisSep 21stNura BioNCT07369076
Added 4 new sites: Toronto, Canada, Utrecht, Netherlands, Krakow, Poland and 1 more

Added 4 new sites: Toronto, Canada, Utrecht, Netherlands, Krakow, Poland and 1 more

sites_addedAmyotrophic Lateral SclerosisSep 21stRegeneron PharmaceuticalsNCT06351592
Added 2 new sites: Krakow, Poland, Huddinge, Sweden

Added 2 new sites: Krakow, Poland, Huddinge, Sweden

sites_removedAlport SyndromeSep 21stBayerNCT07211685
Reduced from 60 to 58 sites

Reduced from 60 to 58 sites

eligibility_changeAlport SyndromeSep 21stBayerNCT07211685
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAdrenocortical CarcinomaSep 21stNational Cancer Institute (NCI)NCT06900595
Added 1 new site: Fort Worth, Texas

Added 1 new site: Fort Worth, Texas

sites_addedWilson DiseaseSep 20thPrime Medicine, Inc.NCT07748403
Added 1 new site: Chicago, Illinois

Added 1 new site: Chicago, Illinois

sites_addedWild-Type ATTR Cardiac AmyloidosisSep 20thAlnylam PharmaceuticalsNCT07052903
Added 12 new sites: Aurora, Colorado, Austin, Texas, Seattle, Washington and 9 more

Added 12 new sites: Aurora, Colorado, Austin, Texas, Seattle, Washington and 9 more

sites_addedWild-Type ATTR Cardiac AmyloidosisSep 20thBayerNCT07298044
Added 6 new sites: Ulm, Germany, Greifswald, Germany, Bonn, Germany and 3 more

Added 6 new sites: Ulm, Germany, Greifswald, Germany, Bonn, Germany and 3 more

Enrollment UpdateWaldenström MacroglobulinemiaSep 19thiOMEDICO AGNCT05326308
Target enrollment increased from 705 to 845

Target enrollment increased from 705 to 845

sites_addedWaldenström MacroglobulinemiaSep 19thNational Cancer Institute (NCI)NCT04840602
Added 6 new sites: Boise, Idaho, Caldwell, Idaho, Meridian, Idaho and 3 more

Added 6 new sites: Boise, Idaho, Caldwell, Idaho, Meridian, Idaho and 3 more

sites_addedVon Willebrand DiseaseSep 19thTakedaNCT05582993
Added 2 new sites: Orlando, Florida, Oxford, United Kingdom

Added 2 new sites: Orlando, Florida, Oxford, United Kingdom

sites_addedVon Willebrand DiseaseSep 19thAlnylam PharmaceuticalsNCT07575308
Added 8 new sites: San Diego, California, San Francisco, California, Pittsburgh, Pennsylvania and 5 more

Added 8 new sites: San Diego, California, San Francisco, California, Pittsburgh, Pennsylvania and 5 more

sites_addedVon Willebrand DiseaseSep 19thHoffmann-La RocheNCT06998524
Added 1 new site: Lexington, Kentucky

Added 1 new site: Lexington, Kentucky

sites_addedVon Willebrand DiseaseSep 19thVega Therapeutics, IncNCT07115004
Added 18 new sites: Palo Alto, California, New Haven, Connecticut, Ann Arbor, Michigan and 15 more

Added 18 new sites: Palo Alto, California, New Haven, Connecticut, Ann Arbor, Michigan and 15 more

sites_removedThalassemiaSep 19thBristol-Myers SquibbNCT05664737
Reduced from 36 to 31 sites

Reduced from 36 to 31 sites

sites_addedThalassemiaSep 19thNovo Nordisk A/SNCT06609226
Expanded from 106 to 107 sites

Expanded from 106 to 107 sites

sites_removedSystemic Juvenile Idiopathic ArthritisSep 19thAbbVieNCT05609630
Reduced from 48 to 45 sites

Reduced from 48 to 45 sites

Enrollment UpdateSystemic Juvenile Idiopathic ArthritisSep 19thChangchun GeneScience Pharmaceutical Co., Ltd.NCT05925452
Target enrollment increased from 221 to 290

Target enrollment increased from 221 to 290

sites_addedStargardt DiseaseSep 19thAstellas Institute for Regenerative MedicineNCT07734064
Added 2 new sites: Cincinnati, Ohio, Dallas, Texas

Added 2 new sites: Cincinnati, Ohio, Dallas, Texas

sites_addedStargardt DiseaseSep 19thAlkeus Pharmaceuticals, Inc.NCT07419334
Added 4 new sites: Boston, Massachusetts, Philadelphia, Pennsylvania, Pittsburgh, Pennsylvania and 1 more

Added 4 new sites: Boston, Massachusetts, Philadelphia, Pennsylvania, Pittsburgh, Pennsylvania and 1 more

sites_removedSpinal Muscular AtrophySep 19thHoffmann-La RocheNCT05115110
Reduced from 35 to 30 sites

Reduced from 35 to 30 sites

Enrollment UpdateSpinal Muscular AtrophySep 19thHoffmann-La RocheNCT05115110
Target enrollment decreased from 259 to 97

Target enrollment decreased from 259 to 97

Enrollment UpdateHereditary Spastic Paraplegia Type 4Sep 19thNational Institute of Neurological Disorders and Stroke (NINDS)NCT01568658
Target enrollment increased from 2323 to 2586

Target enrollment increased from 2323 to 2586

Enrollment UpdateSickle Cell DiseaseSep 19thNovo Nordisk A/SNCT06612268
Target enrollment increased from 408 to 510

Target enrollment increased from 408 to 510

eligibility_changeSickle Cell DiseaseSep 19thNovo Nordisk A/SNCT06612268
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateSickle Cell DiseaseSep 19thNational Heart, Lung, and Blood Institute (NHLBI)NCT05904093
Target enrollment increased from 25 to 35

Target enrollment increased from 25 to 35

sites_addedSickle Cell DiseaseSep 19thNovartis PharmaceuticalsNCT06546670
Added 1 new site: Charlotte, North Carolina

Added 1 new site: Charlotte, North Carolina

sites_addedSickle Cell DiseaseSep 19thNovo Nordisk A/SNCT06609226
Expanded from 106 to 107 sites

Expanded from 106 to 107 sites

sites_addedSickle Cell DiseaseSep 19thNantes University HospitalNCT07274254
Added 1 new site: Bordeaux, France

Added 1 new site: Bordeaux, France

eligibility_changeSickle Cell DiseaseSep 19thNantes University HospitalNCT07274254
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeSickle Cell DiseaseSep 19thSt. Jude Children's Research HospitalNCT07226219
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedSickle Cell DiseaseSep 19thNovartis PharmaceuticalsNCT06439082
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

sites_addedSickle Cell DiseaseSep 19thDisc Medicine, IncNCT07187973
Added 1 new site: Greenville, North Carolina

Added 1 new site: Greenville, North Carolina

sites_addedRett SyndromeSep 19thUCB BIOSCIENCES, Inc.NCT07503444
Added 5 new sites: Miami, Florida, Paris, France, Naples, Italy and 2 more

Added 5 new sites: Miami, Florida, Paris, France, Naples, Italy and 2 more

Enrollment UpdatePulmonary Arterial HypertensionSep 18thParagonix TechnologiesNCT04930289
Target enrollment increased from 2000 to 3500

Target enrollment increased from 2000 to 3500

sites_addedPolycythemia VeraSep 18thNovartis PharmaceuticalsNCT07357727
Added 1 new site: Jinan, China

Added 1 new site: Jinan, China

eligibility_changePolycythemia VeraSep 18thPrelude Therapeutics IncorporatedNCT07469891
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeRett SyndromeSep 18thGenecombio Ltd.NCT06739434
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateRetinitis PigmentosaSep 18thOctant, Inc.NCT07408232
Target enrollment decreased from 32 to 18

Target enrollment decreased from 32 to 18

eligibility_changeRetinitis PigmentosaSep 18thOctant, Inc.NCT07408232
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPulmonary Arterial HypertensionSep 18thInsmed IncorporatedNCT07481981
Added 6 new sites: Kansas City, Kansas, Omaha, Nebraska, Petah Tikva, Israel and 3 more

Added 6 new sites: Kansas City, Kansas, Omaha, Nebraska, Petah Tikva, Israel and 3 more

sites_addedPulmonary Arterial HypertensionSep 18thRegeneron PharmaceuticalsNCT07318597
Added 3 new sites: Omaha, Nebraska, Cincinnati, Ohio, Strasbourg, France

Added 3 new sites: Omaha, Nebraska, Cincinnati, Ohio, Strasbourg, France

sites_addedProgressive Supranuclear PalsySep 18thAdam BoxerNCT07173803
Added 4 new sites: Los Angeles, California, Aurora, Colorado, Cincinnati, Ohio and 1 more

Added 4 new sites: Los Angeles, California, Aurora, Colorado, Cincinnati, Ohio and 1 more

sites_addedPrimary Biliary CholangitisSep 18thGilead SciencesNCT06051617
Added 2 new sites: Creixomil, Portugal, Porto, Portugal

Added 2 new sites: Creixomil, Portugal, Porto, Portugal

Enrollment UpdatePrimary Biliary CholangitisSep 18thGilead SciencesNCT06051617
Target enrollment increased from 318 to 402

Target enrollment increased from 318 to 402

eligibility_changePrimary Biliary CholangitisSep 18thGilead SciencesNCT06051617
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPolycythemia VeraSep 18thNovartis PharmaceuticalsNCT07357727
Added 6 new sites: Seattle, Washington, Aurangabad, India, Padova, Italy and 3 more

Added 6 new sites: Seattle, Washington, Aurangabad, India, Padova, Italy and 3 more

Enrollment UpdatePolycythemia VeraSep 18thAjax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06343805
Target enrollment increased from 76 to 256

Target enrollment increased from 76 to 256

eligibility_changePolycythemia VeraSep 18thAjax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06343805
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPolycythemia VeraSep 18thDisc Medicine, IncNCT05320198
Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

sites_addedParoxysmal Nocturnal HemoglobinuriaSep 18thRegeneron PharmaceuticalsNCT05744921
Added 1 new site: Taichung, Taiwan

Added 1 new site: Taichung, Taiwan

sites_addedNiemann-Pick DiseaseSep 18thSanofiNCT06192576
Added 2 new sites: Columbus, Ohio, St. George, Utah

Added 2 new sites: Columbus, Ohio, St. George, Utah

eligibility_changeNiemann-Pick DiseaseSep 18thSanofiNCT06192576
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelofibrosisSep 17thNovartis PharmaceuticalsNCT07357727
Added 1 new site: Skorzewo, Poland

Added 1 new site: Skorzewo, Poland

Enrollment UpdateMyelofibrosisSep 17thAjax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06343805
Target enrollment increased from 76 to 256

Target enrollment increased from 76 to 256

eligibility_changeMyelofibrosisSep 17thAjax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06343805
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesSep 17thRegeneron PharmaceuticalsNCT05744921
Added 1 new site: Taichung, Taiwan

Added 1 new site: Taichung, Taiwan

sites_addedMyelodysplastic SyndromesSep 17thRyvu Therapeutics SANCT06987058
Added 7 new sites: Nice, France, Pessac, France, Chorzów, Poland and 4 more

Added 7 new sites: Nice, France, Pessac, France, Chorzów, Poland and 4 more

sites_addedMultiple SclerosisSep 17thSanofiNCT07325292
Added 2 new sites: Baltimore, Maryland, Tokyo, Japan

Added 2 new sites: Baltimore, Maryland, Tokyo, Japan

eligibility_changeMultiple SclerosisSep 17thHoffmann-La RocheNCT04586023
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMultiple SclerosisSep 17thHoffmann-La RocheNCT04075266
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisSep 17thZenas BioPharma (USA), LLCNCT07299019
Added 5 new sites: Columbus, Ohio, Plovdiv, Bulgaria, Sofia, Bulgaria and 2 more

Added 5 new sites: Columbus, Ohio, Plovdiv, Bulgaria, Sofia, Bulgaria and 2 more

sites_addedMultiple SclerosisSep 17thTG Therapeutics, Inc.NCT06433752
Added 17 new sites: Cullman, Alabama, Gainesville, Florida, Orlando, Florida and 14 more

Added 17 new sites: Cullman, Alabama, Gainesville, Florida, Orlando, Florida and 14 more

sites_addedMyotonic DystrophySep 17thAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Genova, Italy

Added 1 new site: Genova, Italy

sites_addedMyelofibrosisSep 17thDisc Medicine, IncNCT05320198
Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

sites_addedMyelofibrosisSep 17thNovartis PharmaceuticalsNCT07357727
Added 7 new sites: Seattle, Washington, Aurangabad, India, Padova, Italy and 4 more

Added 7 new sites: Seattle, Washington, Aurangabad, India, Padova, Italy and 4 more

sites_addedMyelodysplastic SyndromesSep 17thBeOne MedicinesNCT04771130
Added 1 new site: Auckland, New Zealand

Added 1 new site: Auckland, New Zealand

sites_addedMyelodysplastic SyndromesSep 17thDisc Medicine, IncNCT05320198
Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

Enrollment UpdateMyelodysplastic SyndromesSep 17thSwedish Orphan BiovitrumNCT06782373
Target enrollment increased from 78 to 156

Target enrollment increased from 78 to 156

eligibility_changeMyelodysplastic SyndromesSep 17thSwedish Orphan BiovitrumNCT06782373
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesSep 17thYale UniversityNCT07096297
Added 1 new site: Columbus, Ohio

Added 1 new site: Columbus, Ohio

sites_addedMyasthenia GravisSep 17thMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT06463587
Added 5 new sites: Belgrade, Serbia, Niš, Serbia, Novi Sad, Serbia and 2 more

Added 5 new sites: Belgrade, Serbia, Niš, Serbia, Novi Sad, Serbia and 2 more

sites_addedMyasthenia GravisSep 17thargenxNCT06392386
Added 1 new site: Randwick, Australia

Added 1 new site: Randwick, Australia

sites_addedMultiple System AtrophySep 17thTeva Branded Pharmaceutical Products R&D LLCNCT07197866
Added 2 new sites: Marseille, France, Fuchū, Japan

Added 2 new sites: Marseille, France, Fuchū, Japan

eligibility_changeMultiple SclerosisSep 17thUniversity of CalgaryNCT06261489
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisSep 17thNational Institute of Allergy and Infectious Diseases (NIAID)NCT04047628
Added 1 new site: Detroit, Michigan

Added 1 new site: Detroit, Michigan

sites_addedMultiple SclerosisSep 17thZenas BioPharma (USA), LLCNCT07067463
Added 2 new sites: Tampa, Florida, Hradec Králové, Czechia

Added 2 new sites: Tampa, Florida, Hradec Králové, Czechia

sites_addedMultiple SclerosisSep 17thRegeneron PharmaceuticalsNCT06351592
Added 2 new sites: Krakow, Poland, Huddinge, Sweden

Added 2 new sites: Krakow, Poland, Huddinge, Sweden

sites_removedMultiple SclerosisSep 17thHoffmann-La RocheNCT05704361
Reduced from 32 to 26 sites

Reduced from 32 to 26 sites

eligibility_changeMultiple SclerosisSep 17thNational Cancer Institute (NCI)NCT03816345
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMesotheliomaSep 17thMemorial Sloan Kettering Cancer CenterNCT07532902
Eligibility criteria have been updated

Eligibility criteria have been updated

phase_changeMesotheliomaSep 17thInSilico Medicine Hong Kong LimitedNCT06566079
Moved from Phase 1 to Phase 1, Phase 2

Moved from Phase 1 to Phase 1, Phase 2

Enrollment UpdateMesotheliomaSep 17thInSilico Medicine Hong Kong LimitedNCT06566079
Target enrollment increased from 100 to 160

Target enrollment increased from 100 to 160

eligibility_changeMesotheliomaSep 17thInSilico Medicine Hong Kong LimitedNCT06566079
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMerkel Cell CarcinomaSep 17thSystImmune Inc.NCT07080242
Added 4 new sites: Glendale, California, Long Beach, California, New Orleans, Louisiana and 1 more

Added 4 new sites: Glendale, California, Long Beach, California, New Orleans, Louisiana and 1 more

eligibility_changeMerkel Cell CarcinomaSep 17thSystImmune Inc.NCT07080242
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMerkel Cell CarcinomaSep 17thNeonc Technologies, Inc.NCT06047379
Added 1 new site: Boston, Massachusetts

Added 1 new site: Boston, Massachusetts

Enrollment UpdateMedullary Thyroid CancerSep 17thNational Cancer Institute (NCI)NCT01660984
Target enrollment decreased from 259 to 105

Target enrollment decreased from 259 to 105

sites_addedImmune ThrombocytopeniaSep 16thTakedaNCT06722235
Added 2 new sites: Madrid, Spain, Malmö, Sweden

Added 2 new sites: Madrid, Spain, Malmö, Sweden

sites_addedIgA NephropathySep 16thTakedaNCT06963827
Added 2 new sites: Olomouc, Czechia, Birmingham, United Kingdom

Added 2 new sites: Olomouc, Czechia, Birmingham, United Kingdom

sites_addedIgA NephropathySep 16thBiogenNCT06935357
Added 1 new site: La Boca, Argentina

Added 1 new site: La Boca, Argentina

sites_addedHodgkin LymphomaSep 16thNovartis PharmaceuticalsNCT04094311
Expanded from 54 to 55 sites

Expanded from 54 to 55 sites

sites_addedHodgkin LymphomaSep 16thAutolus LimitedNCT06173518
Added 1 new site: New York, New York

Added 1 new site: New York, New York

sites_removedHodgkin LymphomaSep 16thCelgeneNCT04884035
Reduced from 43 to 36 sites

Reduced from 43 to 36 sites

sites_addedHodgkin LymphomaSep 16thNational Cancer Institute (NCI)NCT04840602
Added 6 new sites: Boise, Idaho, Caldwell, Idaho, Meridian, Idaho and 3 more

Added 6 new sites: Boise, Idaho, Caldwell, Idaho, Meridian, Idaho and 3 more

sites_addedHodgkin LymphomaSep 16thFondazione Italiana Linfomi - ETSNCT05977673
Added 2 new sites: Novara, Italy, Reggio Emilia, Italy

Added 2 new sites: Novara, Italy, Reggio Emilia, Italy

sites_addedHodgkin LymphomaSep 16thRegeneron PharmaceuticalsNCT06149286
Added 4 new sites: Essen, Germany, Bydgoszcz, Poland, Kaohsiung City, Taiwan and 1 more

Added 4 new sites: Essen, Germany, Bydgoszcz, Poland, Kaohsiung City, Taiwan and 1 more

Enrollment UpdateHodgkin LymphomaSep 16thRegeneron PharmaceuticalsNCT06149286
Target enrollment increased from 470 to 580

Target enrollment increased from 470 to 580

eligibility_changeHodgkin LymphomaSep 16thRegeneron PharmaceuticalsNCT06149286
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHemophilia BSep 16thCSL BehringNCT07080905
Added 1 new site: Brisbane, Australia

Added 1 new site: Brisbane, Australia

sites_addedLennox-Gastaut SyndromeSep 16thLongboard PharmaceuticalsNCT06908226
Added 53 new sites: Los Angeles, California, Palo Alto, California, Aurora, Colorado and 50 more

Added 53 new sites: Los Angeles, California, Palo Alto, California, Aurora, Colorado and 50 more

sites_addedLennox-Gastaut SyndromeSep 16thEpygenixNCT05066217
Added 3 new sites: Dallas, Texas, Genoa, Italy, Belgrade, Serbia

Added 3 new sites: Dallas, Texas, Genoa, Italy, Belgrade, Serbia

Enrollment UpdateIdiopathic Pulmonary FibrosisSep 16thMannkind CorporationNCT07679893
Target enrollment decreased from 210 to 153

Target enrollment decreased from 210 to 153

sites_addedIdiopathic Pulmonary FibrosisSep 16thTrevi TherapeuticsNCT07671911
Added 4 new sites: Kissimmee, Florida, New Orleans, Louisiana, Winston-Salem, North Carolina and 1 more

Added 4 new sites: Kissimmee, Florida, New Orleans, Louisiana, Winston-Salem, North Carolina and 1 more

eligibility_changeIdiopathic Pulmonary FibrosisSep 16thTrevi TherapeuticsNCT07671911
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHodgkin LymphomaSep 16thNorthwestern UniversityNCT06242834
Target enrollment decreased from 32 to 11

Target enrollment decreased from 32 to 11

eligibility_changeHodgkin LymphomaSep 16thNorthwestern UniversityNCT06242834
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedHodgkin LymphomaSep 16thFondazione Italiana Linfomi - ETSNCT05300282
Reduced from 32 to 28 sites

Reduced from 32 to 28 sites

Enrollment UpdateHodgkin LymphomaSep 16thHoffmann-La RocheNCT06806033
Target enrollment increased from 100 to 130

Target enrollment increased from 100 to 130

eligibility_changeHodgkin LymphomaSep 16thHoffmann-La RocheNCT06806033
Eligibility criteria have been updated

Eligibility criteria have been updated

phase_changeHodgkin LymphomaSep 16thM.D. Anderson Cancer CenterNCT07153796
Moved from Phase 2 to Phase 1, Phase 2

Moved from Phase 2 to Phase 1, Phase 2

sites_removedHodgkin LymphomaSep 16thLyell Immunopharma, Inc.NCT07188558
Reduced from 39 to 36 sites

Reduced from 39 to 36 sites

sites_addedHodgkin LymphomaSep 16thEastern Cooperative Oncology GroupNCT06724237
Added 7 new sites: Washington D.C., District of Columbia, Burr Ridge, Illinois, Homer Glen, Illinois and 4 more

Added 7 new sites: Washington D.C., District of Columbia, Burr Ridge, Illinois, Homer Glen, Illinois and 4 more

sites_addedHodgkin LymphomaSep 16thNational Cancer Institute (NCI)NCT07003295
Added 1 new site: Lexington, Kentucky

Added 1 new site: Lexington, Kentucky

sites_addedHodgkin LymphomaSep 16thEli Lilly and CompanyNCT07101328
Added 1 new site: Tokyo, Japan

Added 1 new site: Tokyo, Japan

sites_addedHodgkin LymphomaSep 16thFondazione Italiana Linfomi - ETSNCT05524298
Added 1 new site: Torino, Italy

Added 1 new site: Torino, Italy

sites_addedHodgkin LymphomaSep 16thAstraZenecaNCT06564038
Expanded from 64 to 65 sites

Expanded from 64 to 65 sites

sites_removedHodgkin LymphomaSep 16thBeOne MedicinesNCT05100862
Reduced from 266 to 264 sites

Reduced from 266 to 264 sites

sites_addedHodgkin LymphomaSep 16thNational Cancer Institute (NCI)NCT07332507
Added 3 new sites: Irvine, California, Los Angeles, California, Orange, California

Added 3 new sites: Irvine, California, Los Angeles, California, Orange, California

Enrollment UpdateHodgkin LymphomaSep 16thM.D. Anderson Cancer CenterNCT06108232
Target enrollment increased from 33 to 83

Target enrollment increased from 33 to 83

sites_addedHodgkin LymphomaSep 16thMerck Sharp & Dohme LLCNCT06717347
Added 5 new sites: Athens, Georgia, Reno, Nevada, Shirley, New York and 2 more

Added 5 new sites: Athens, Georgia, Reno, Nevada, Shirley, New York and 2 more

sites_addedHodgkin LymphomaSep 16thTempus AINCT07154823
Added 1 new site: Charlotte, North Carolina

Added 1 new site: Charlotte, North Carolina

sites_addedHodgkin LymphomaSep 16thMission TherapeuticsNCT07630545
Added 13 new sites: Adelaide, Australia, Melbourne, Australia, Melbourne, Australia and 10 more

Added 13 new sites: Adelaide, Australia, Melbourne, Australia, Melbourne, Australia and 10 more

eligibility_changeHodgkin LymphomaSep 16thMission TherapeuticsNCT07630545
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 16thBristol-Myers SquibbNCT06090539
Added 4 new sites: Suzhou, China, Shenyang, China, Chuo-ku, Japan and 1 more

Added 4 new sites: Suzhou, China, Shenyang, China, Chuo-ku, Japan and 1 more

sites_addedHodgkin LymphomaSep 16thHoffmann-La RocheNCT07200375
Added 1 new site: Hong Kong, Hong Kong

Added 1 new site: Hong Kong, Hong Kong

Enrollment UpdateHodgkin LymphomaSep 16thFred Hutchinson Cancer CenterNCT03779854
Target enrollment decreased from 68 to 45

Target enrollment decreased from 68 to 45

sites_removedHodgkin LymphomaSep 16thFondazione Italiana Linfomi - ETSNCT06492837
Reduced from 24 to 20 sites

Reduced from 24 to 20 sites

sites_addedHodgkin LymphomaSep 16thNational Cancer Institute (NCI)NCT05675410
Added 5 new sites: Boise, Idaho, Caldwell, Idaho, Meridian, Idaho and 2 more

Added 5 new sites: Boise, Idaho, Caldwell, Idaho, Meridian, Idaho and 2 more

eligibility_changeFocal EpilepsySep 15thNaviFUS CorporationNCT06388707
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedEssential ThrombocythemiaSep 15thNovartis PharmaceuticalsNCT07357727
Added 3 new sites: Seattle, Washington, Aurangabad, India, Katowice, Poland

Added 3 new sites: Seattle, Washington, Aurangabad, India, Katowice, Poland

sites_addedEssential ThrombocythemiaSep 15thDisc Medicine, IncNCT05320198
Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

Added 2 new sites: East Brunswick, New Jersey, Maumee, Ohio

phase_changeGeographic AtrophySep 15thJanssen Research & Development, LLCNCT06635148
Moved from Phase 2 to Phase 2, Phase 3

Moved from Phase 2 to Phase 2, Phase 3

sites_removedEssential ThrombocythemiaSep 15thIncyte CorporationNCT07623200
Reduced from 177 to 175 sites

Reduced from 177 to 175 sites

sites_addedEssential ThrombocythemiaSep 15thNovartis PharmaceuticalsNCT07357727
Added 2 new sites: Kobe, Japan, Fukuoka, Japan

Added 2 new sites: Kobe, Japan, Fukuoka, Japan

sites_addedPrimary HyperoxaluriaSep 14thNovartis PharmaceuticalsNCT07681271
Added 3 new sites: Shanghai, China, Singapore, Singapore, Icheon, South Korea

Added 3 new sites: Shanghai, China, Singapore, Singapore, Icheon, South Korea

sites_addedPolycythemia VeraSep 14thNovartis PharmaceuticalsNCT07357727
Added 2 new sites: Kobe, Japan, Fukuoka, Japan

Added 2 new sites: Kobe, Japan, Fukuoka, Japan

Enrollment UpdatePheochromocytomaSep 14thNational Cancer Institute (NCI)NCT01660984
Target enrollment decreased from 259 to 105

Target enrollment decreased from 259 to 105

Enrollment UpdateParagangliomaSep 14thNational Cancer Institute (NCI)NCT01660984
Target enrollment decreased from 259 to 105

Target enrollment decreased from 259 to 105

sites_addedPulmonary Arterial HypertensionSep 14thMerck Sharp & Dohme LLCNCT07646860
Added 2 new sites: Izumi, Japan, Suita, Japan

Added 2 new sites: Izumi, Japan, Suita, Japan

sites_addedPulmonary Arterial HypertensionSep 14thTenax Therapeutics, Inc.NCT07436689
Added 2 new sites: Boston, Massachusetts, Durham, North Carolina

Added 2 new sites: Boston, Massachusetts, Durham, North Carolina

sites_addedPulmonary Arterial HypertensionSep 14thUniversity of GiessenNCT06409624
Added 1 new site: Bad Nauheim, Germany

Added 1 new site: Bad Nauheim, Germany

Enrollment UpdatePulmonary Arterial HypertensionSep 14thUniversity of GiessenNCT06409624
Target enrollment increased from 350 to 400

Target enrollment increased from 350 to 400

eligibility_changePulmonary Arterial HypertensionSep 14thUniversity of GiessenNCT06409624
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changePulmonary Arterial HypertensionSep 14thNational Institutes of Health Clinical Center (CC)NCT01712620
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPulmonary Arterial HypertensionSep 14th35Pharma Inc., a GSK companyNCT07143448
Added 2 new sites: Providence, Rhode Island, London, United Kingdom

Added 2 new sites: Providence, Rhode Island, London, United Kingdom

sites_addedPulmonary Arterial HypertensionSep 14thMerck Sharp & Dohme LLCNCT07218029
Added 1 new site: Darlinghurst, Australia

Added 1 new site: Darlinghurst, Australia

sites_addedPulmonary Arterial HypertensionSep 14thPulmovant, Inc.NCT06635850
Added 85 new sites: Phoenix, Arizona, Los Angeles, California, Sacramento, California and 82 more

Added 85 new sites: Phoenix, Arizona, Los Angeles, California, Sacramento, California and 82 more

eligibility_changePulmonary Arterial HypertensionSep 14thPulmovant, Inc.NCT06635850
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPrimary HyperoxaluriaSep 14thYolTech Therapeutics Co., LtdNCT07587021
Added 3 new sites: Aurora, Colorado, St Louis, Missouri, Philadelphia, Pennsylvania

Added 3 new sites: Aurora, Colorado, St Louis, Missouri, Philadelphia, Pennsylvania

sites_addedPolycythemia VeraSep 14thOno Pharmaceutical Co., Ltd.NCT07429266
Added 2 new sites: Macon, Georgia, Nagasaki, Japan

Added 2 new sites: Macon, Georgia, Nagasaki, Japan

sites_removedPolycythemia VeraSep 14thNovartis PharmaceuticalsNCT07340138
Reduced from 7 to 3 sites

Reduced from 7 to 3 sites

Enrollment UpdatePolycythemia VeraSep 14thNovartis PharmaceuticalsNCT07340138
Target enrollment decreased from 6 to 3

Target enrollment decreased from 6 to 3

sites_addedPolycythemia VeraSep 14thNovartis PharmaceuticalsNCT07357727
Added 10 new sites: Indianapolis, Indiana, Albany, New York, Verona, Italy and 7 more

Added 10 new sites: Indianapolis, Indiana, Albany, New York, Verona, Italy and 7 more

eligibility_changeNeuromyelitis OpticaSep 13thTG Therapeutics, Inc.NCT06680037
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedNarcolepsy Type 1Sep 13thCentessa Pharmaceuticals (UK) LimitedNCT07598708
Added 5 new sites: Birmingham, Alabama, Brandon, Florida, Austin, Texas and 2 more

Added 5 new sites: Birmingham, Alabama, Brandon, Florida, Austin, Texas and 2 more

sites_addedMyotonic DystrophySep 13thAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Oxford, United Kingdom

Added 1 new site: Oxford, United Kingdom

sites_removedMyelofibrosisSep 13thNovartis PharmaceuticalsNCT07340138
Reduced from 7 to 3 sites

Reduced from 7 to 3 sites

Enrollment UpdateMyelofibrosisSep 13thNovartis PharmaceuticalsNCT07340138
Target enrollment decreased from 6 to 3

Target enrollment decreased from 6 to 3

sites_addedMyelofibrosisSep 13thNovartis PharmaceuticalsNCT07357727
Added 10 new sites: Indianapolis, Indiana, Albany, New York, Verona, Italy and 7 more

Added 10 new sites: Indianapolis, Indiana, Albany, New York, Verona, Italy and 7 more

eligibility_changeMyelodysplastic SyndromesSep 13thNational Heart, Lung, and Blood Institute (NHLBI)NCT03173937
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMyelodysplastic SyndromesSep 13thNational Cancer Institute (NCI)NCT01861106
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyasthenia GravisSep 13thAstraZenecaNCT07247279
Expanded from 7 to 8 sites

Expanded from 7 to 8 sites

sites_addedMyasthenia GravisSep 13thUCB Biopharma SRLNCT07463521
Added 4 new sites: Chengdu, China, Nanchang, China, Suzhou, China and 1 more

Added 4 new sites: Chengdu, China, Nanchang, China, Suzhou, China and 1 more

eligibility_changeMyasthenia GravisSep 13thTG Therapeutics, Inc.NCT06680037
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyasthenia GravisSep 13thVertex Pharmaceuticals IncorporatedNCT07501702
Added 1 new site: Kocaeli, Turkey (Türkiye)

Added 1 new site: Kocaeli, Turkey (Türkiye)

sites_removedMultiple System AtrophySep 13thHoffmann-La RocheNCT05115110
Reduced from 35 to 30 sites

Reduced from 35 to 30 sites

Enrollment UpdateMultiple System AtrophySep 13thHoffmann-La RocheNCT05115110
Target enrollment decreased from 259 to 97

Target enrollment decreased from 259 to 97

sites_addedMultiple SclerosisSep 13thZenas BioPharma (USA), LLCNCT07299019
Added 1 new site: Guaynabo, Puerto Rico

Added 1 new site: Guaynabo, Puerto Rico

sites_addedMultiple SclerosisSep 13thZenas BioPharma (USA), LLCNCT07067463
Added 8 new sites: Columbus, Ohio, Milwaukee, Wisconsin, Teplice, Czechia and 5 more

Added 8 new sites: Columbus, Ohio, Milwaukee, Wisconsin, Teplice, Czechia and 5 more

sites_addedMultiple SclerosisSep 13thGenentech, Inc.NCT07609719
Added 2 new sites: Atlanta, Georgia, Cordova, Tennessee

Added 2 new sites: Atlanta, Georgia, Cordova, Tennessee

sites_addedMultiple SclerosisSep 13thUniversity of CalgaryNCT06261489
Added 1 new site: Calgary, Canada

Added 1 new site: Calgary, Canada

eligibility_changeMultiple SclerosisSep 13thTG Therapeutics, Inc.NCT06680037
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMultiple SclerosisSep 13thJung Diagnostics GmbHNCT07753928
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMesotheliomaSep 13thAstraZenecaNCT06535607
Expanded from 97 to 98 sites

Expanded from 97 to 98 sites

sites_removedMembranous NephropathySep 13thBeOne MedicinesNCT05707377
Reduced from 47 to 45 sites

Reduced from 47 to 45 sites

Enrollment UpdateLimb-Girdle Muscular DystrophySep 12thML Bio Solutions, Inc.NCT05775848
Target enrollment increased from 81 to 112

Target enrollment increased from 81 to 112

sites_addedLight Chain AmyloidosisSep 12thTianjin Medical UniversityNCT07232459
Added 1 new site: Qingdao, China

Added 1 new site: Qingdao, China

eligibility_changeIgA NephropathySep 12thPurespring Therapeutics LimitedNCT07182227
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedIgA NephropathySep 12thNovartis PharmaceuticalsNCT06994845
Added 4 new sites: Madera, California, Gainesville, Florida, Córdoba, Argentina and 1 more

Added 4 new sites: Madera, California, Gainesville, Florida, Córdoba, Argentina and 1 more

sites_addedHereditary AngioedemaSep 12thADARx Pharmaceuticals, Inc.NCT06960213
Added 18 new sites: Scottsdale, Arizona, Santa Monica, California, Centennial, Colorado and 15 more

Added 18 new sites: Scottsdale, Arizona, Santa Monica, California, Centennial, Colorado and 15 more

sites_addedIdiopathic Pulmonary FibrosisSep 12thContineum TherapeuticsNCT07284459
Added 3 new sites: Buenos Aires, Argentina, Toronto, Canada, Trois-Rivières, Canada

Added 3 new sites: Buenos Aires, Argentina, Toronto, Canada, Trois-Rivières, Canada

sites_removedHunter SyndromeSep 12thDenali Therapeutics Inc.NCT05371613
Reduced from 32 to 30 sites

Reduced from 32 to 30 sites

sites_removedHomozygous Familial HypercholesterolemiaSep 12thCRISPR Therapeutics AGNCT07491172
Reduced from 19 to 17 sites

Reduced from 19 to 17 sites

eligibility_changeHodgkin LymphomaSep 12thAmerican Society of Clinical OncologyNCT02693535
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 12thYazeed SawalhaNCT06536049
Added 1 new site: Richmond, Virginia

Added 1 new site: Richmond, Virginia

Enrollment UpdateHodgkin LymphomaSep 12thiOMEDICO AGNCT05326308
Target enrollment increased from 705 to 845

Target enrollment increased from 705 to 845

eligibility_changeHodgkin LymphomaSep 12thAbbVieNCT07387471
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 12thMerck Sharp & Dohme LLCNCT07519772
Added 4 new sites: Pilar, Argentina, Santiago, Chile, Giessen, Germany and 1 more

Added 4 new sites: Pilar, Argentina, Santiago, Chile, Giessen, Germany and 1 more

sites_removedHodgkin LymphomaSep 12thHoffmann-La RocheNCT02568267
Reduced from 130 to 120 sites

Reduced from 130 to 120 sites

sites_addedHodgkin LymphomaSep 12thNovartis PharmaceuticalsNCT07422610
Added 2 new sites: Milan, Italy, Milan, Italy

Added 2 new sites: Milan, Italy, Milan, Italy

eligibility_changeHodgkin LymphomaSep 12thTreeline Biosciences, Inc.NCT07082803
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 12thNational Cancer Institute (NCI)NCT03739814
Added 3 new sites: Evanston, Illinois, Glenview, Illinois, Highland Park, Illinois

Added 3 new sites: Evanston, Illinois, Glenview, Illinois, Highland Park, Illinois

sites_removedHodgkin LymphomaSep 12thImugene LimitedNCT03666000
Reduced from 23 to 15 sites

Reduced from 23 to 15 sites

eligibility_changeHodgkin LymphomaSep 12thImugene LimitedNCT03666000
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHereditary Spastic ParaplegiaSep 12thNational Institute of Neurological Disorders and Stroke (NINDS)NCT01568658
Target enrollment increased from 2323 to 2586

Target enrollment increased from 2323 to 2586

sites_addedHemophilia BSep 11thRegeneron PharmaceuticalsNCT06379789
Added 3 new sites: Vitória, Brazil, Campinas, Brazil, Rio de Janeiro, Brazil

Added 3 new sites: Vitória, Brazil, Campinas, Brazil, Rio de Janeiro, Brazil

sites_addedHemophilia ASep 11thRegeneron PharmaceuticalsNCT06379789
Added 3 new sites: Vitória, Brazil, Campinas, Brazil, Rio de Janeiro, Brazil

Added 3 new sites: Vitória, Brazil, Campinas, Brazil, Rio de Janeiro, Brazil

eligibility_changeHemophilia ASep 11thHoffmann-La RocheNCT05987449
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedFocal EpilepsySep 11thXenon Pharmaceuticals Inc.NCT05718817
Added 1 new site: Heeze, Netherlands

Added 1 new site: Heeze, Netherlands

sites_addedHemophilia ASep 11thHoffmann-La RocheNCT07416526
Added 9 new sites: Godoy Cruz, Argentina, Ribeirão Preto, Brazil, Copenhaen, Denmark and 6 more

Added 9 new sites: Godoy Cruz, Argentina, Ribeirão Preto, Brazil, Copenhaen, Denmark and 6 more

sites_removedHemophilia ASep 11thNovo Nordisk A/SNCT05685238
Reduced from 152 to 141 sites

Reduced from 152 to 141 sites

sites_addedGeographic AtrophySep 11thNovartis PharmaceuticalsNCT07441642
Added 4 new sites: Barranquilla, Colombia, Kobe, Japan, Newcastle upon Tyne, United Kingdom and 1 more

Added 4 new sites: Barranquilla, Colombia, Kobe, Japan, Newcastle upon Tyne, United Kingdom and 1 more

sites_addedGeographic AtrophySep 11thONL TherapeuticsNCT06659445
Added 3 new sites: Chevy Chase, Maryland, Hagerstown, Maryland, San Antonio, Texas

Added 3 new sites: Chevy Chase, Maryland, Hagerstown, Maryland, San Antonio, Texas

sites_addedGastrointestinal Stromal TumorSep 11thGlaxoSmithKlineNCT07218926
Added 34 new sites: Duarte, California, Upland, California, Aurora, Colorado and 31 more

Added 34 new sites: Duarte, California, Upland, California, Aurora, Colorado and 31 more

sites_addedFocal Segmental GlomerulosclerosisSep 11thBoehringer IngelheimNCT07220083
Added 7 new sites: Kansas City, Kansas, Orangeburg, South Carolina, Conroe, Texas and 4 more

Added 7 new sites: Kansas City, Kansas, Orangeburg, South Carolina, Conroe, Texas and 4 more

sites_removedEssential ThrombocythemiaSep 11thNovartis PharmaceuticalsNCT07340138
Reduced from 7 to 3 sites

Reduced from 7 to 3 sites

Enrollment UpdateEssential ThrombocythemiaSep 11thNovartis PharmaceuticalsNCT07340138
Target enrollment decreased from 6 to 3

Target enrollment decreased from 6 to 3

sites_addedEssential ThrombocythemiaSep 11thNovartis PharmaceuticalsNCT07357727
Added 10 new sites: Indianapolis, Indiana, Albany, New York, Verona, Italy and 7 more

Added 10 new sites: Indianapolis, Indiana, Albany, New York, Verona, Italy and 7 more

eligibility_changeDuchenne Muscular DystrophySep 10thWest China HospitalNCT06114056
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDermatomyositisSep 10thAllogene TherapeuticsNCT07085104
Added 2 new sites: Baltimore, Maryland, Charlotte, North Carolina

Added 2 new sites: Baltimore, Maryland, Charlotte, North Carolina

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 10thImmunovant Sciences GmbHNCT07032662
Added 1 new site: Buenos Aires, Argentina

Added 1 new site: Buenos Aires, Argentina

sites_addedChronic Graft-versus-Host DiseaseSep 10thGilead SciencesNCT07096193
Added 8 new sites: La Jolla, California, Hanover, Germany, Ankara, Turkey (Türkiye) and 5 more

Added 8 new sites: La Jolla, California, Hanover, Germany, Ankara, Turkey (Türkiye) and 5 more

sites_addedChronic Graft-versus-Host DiseaseSep 10thGranular Therapeutics LimitedNCT07181369
Added 1 new site: Halle, Germany

Added 1 new site: Halle, Germany

sites_addedChronic Graft-versus-Host DiseaseSep 10thWeill Medical College of Cornell UniversityNCT06168058
Added 1 new site: New Hyde Park, New York

Added 1 new site: New Hyde Park, New York

sites_addedChronic Graft-versus-Host DiseaseSep 10thAstraZenecaNCT06564038
Expanded from 64 to 65 sites

Expanded from 64 to 65 sites

sites_addedChronic Graft-versus-Host DiseaseSep 10thAiriver Medical, Inc.NCT07290140
Added 2 new sites: Charleston, South Carolina, Charleston, South Carolina

Added 2 new sites: Charleston, South Carolina, Charleston, South Carolina

eligibility_changeChronic Graft-versus-Host DiseaseSep 10thUniversity of California, Los AngelesNCT04556890
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedCholangiocarcinomaSep 10thFrancesco De CobelliNCT06375915
Added 3 new sites: Bergamo, Italy, Pisa, Italy, Naples, Italy

Added 3 new sites: Bergamo, Italy, Pisa, Italy, Naples, Italy

sites_addedDuchenne Muscular DystrophySep 10thAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Oxford, United Kingdom

Added 1 new site: Oxford, United Kingdom

Enrollment UpdateDilated CardiomyopathySep 10thAstraZenecaNCT07241104
Target enrollment decreased from 31 to 23

Target enrollment decreased from 31 to 23

eligibility_changeDilated CardiomyopathySep 10thAstraZenecaNCT07241104
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeCystic FibrosisSep 10thRoyal College of Surgeons, IrelandNCT04602468
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateCystic FibrosisSep 10thAstraZenecaNCT07245407
Target enrollment decreased from 320 to 251

Target enrollment decreased from 320 to 251

sites_addedCushing DiseaseSep 10thSparrow PharmaceuticalsNCT07296484
Added 3 new sites: Winter Park, Florida, Wichita, Kansas, Vienna, Virginia

Added 3 new sites: Winter Park, Florida, Wichita, Kansas, Vienna, Virginia

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 10thGrifols Therapeutics LLCNCT07540221
Added 3 new sites: Hradec Králové, Czechia, Bydgoszcz, Poland, Katowice, Poland

Added 3 new sites: Hradec Králové, Czechia, Bydgoszcz, Poland, Katowice, Poland

eligibility_changeChronic Inflammatory Demyelinating PolyneuropathySep 10thTG Therapeutics, Inc.NCT06680037
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Granulomatous DiseaseSep 10thNational Institute of Allergy and Infectious Diseases (NIAID)NCT06253507
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 10thNovartis PharmaceuticalsNCT06868212
Added 5 new sites: Palo Alto, California, Chicago, Illinois, Boston, Massachusetts and 2 more

Added 5 new sites: Palo Alto, California, Chicago, Illinois, Boston, Massachusetts and 2 more

sites_addedChronic Graft-versus-Host DiseaseSep 10thAstraZenecaNCT06542250
Added 1 new site: Göttingen, Germany

Added 1 new site: Göttingen, Germany

sites_addedChronic Graft-versus-Host DiseaseSep 10thAstraZenecaNCT07509151
Added 14 new sites: La Jolla, California, Denver, Colorado, New Haven, Connecticut and 11 more

Added 14 new sites: La Jolla, California, Denver, Colorado, New Haven, Connecticut and 11 more

sites_addedChronic Graft-versus-Host DiseaseSep 10thAkebia TherapeuticsNCT07268638
Added 11 new sites: Boca Raton, Florida, Hialeah, Florida, Worcester, Massachusetts and 8 more

Added 11 new sites: Boca Raton, Florida, Hialeah, Florida, Worcester, Massachusetts and 8 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 10thAkebia TherapeuticsNCT07268638
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 10thUniversity of PittsburghNCT06605807
Target enrollment decreased from 150 to 64

Target enrollment decreased from 150 to 64

sites_addedChronic Graft-versus-Host DiseaseSep 10thCytokineticsNCT06736574
Added 27 new sites: Nanning, China, Chifeng, China, Xuzhou, China and 24 more

Added 27 new sites: Nanning, China, Chifeng, China, Xuzhou, China and 24 more

sites_addedChronic Graft-versus-Host DiseaseSep 10thAstraZenecaNCT07662135
Added 2 new sites: Sun City, Arizona, Calicut, India

Added 2 new sites: Sun City, Arizona, Calicut, India

eligibility_changeChronic Graft-versus-Host DiseaseSep 10thEnsomaNCT06876363
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseSep 10thVA Office of Research and DevelopmentNCT04124029
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 10thNewave Pharmaceutical IncNCT07342478
Added 1 new site: Skokie, Illinois

Added 1 new site: Skokie, Illinois

sites_addedChronic Graft-versus-Host DiseaseSep 10thViridian Therapeutics, Inc.NCT06625398
Added 24 new sites: San Diego, California, Berlin, Germany, Dresden, Germany and 21 more

Added 24 new sites: San Diego, California, Berlin, Germany, Dresden, Germany and 21 more

sites_addedChronic Graft-versus-Host DiseaseSep 10thMerck Sharp & Dohme LLCNCT06136559
Added 2 new sites: Boise, Idaho, Iowa City, Iowa

Added 2 new sites: Boise, Idaho, Iowa City, Iowa

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 10thBoston UniversityNCT05503173
Target enrollment decreased from 385 to 253

Target enrollment decreased from 385 to 253

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 10thSanofiNCT06087627
Target enrollment decreased from 150 to 110

Target enrollment decreased from 150 to 110

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 10thWashington University School of MedicineNCT07020273
Target enrollment decreased from 5000 to 3543

Target enrollment decreased from 5000 to 3543

eligibility_changeChronic Graft-versus-Host DiseaseSep 10thMassachusetts General HospitalNCT06843902
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 10thUniversity of South CarolinaNCT06096701
Target enrollment decreased from 540 to 421

Target enrollment decreased from 540 to 421

sites_addedChronic Graft-versus-Host DiseaseSep 10thBiocadNCT07119372
Added 14 new sites: Krasnodar, Russia, Krasnodar, Russia, Novosibirsk, Russia and 11 more

Added 14 new sites: Krasnodar, Russia, Krasnodar, Russia, Novosibirsk, Russia and 11 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 10thBiocadNCT07119372
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 10thSanofiNCT07190209
Added 55 new sites: Miami, Florida, Miami, Florida, Chicago, Illinois and 52 more

Added 55 new sites: Miami, Florida, Miami, Florida, Chicago, Illinois and 52 more

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Sep 9thAlnylam PharmaceuticalsNCT07358078
Added 20 new sites: Tucson, Arizona, Beverly Hills, California, Kansas City, Kansas and 17 more

Added 20 new sites: Tucson, Arizona, Beverly Hills, California, Kansas City, Kansas and 17 more

eligibility_changeAmyotrophic Lateral SclerosisSep 9thUniversity of IowaNCT07224269
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAmyotrophic Lateral SclerosisSep 9thTrace Neuroscience, Inc.NCT07674667
Added 2 new sites: Rostock, Germany, Sheffield, United Kingdom

Added 2 new sites: Rostock, Germany, Sheffield, United Kingdom

sites_addedBecker Muscular DystrophySep 9thAvidity Biosciences, Inc.NCT07587242
Added 1 new site: Oxford, United Kingdom

Added 1 new site: Oxford, United Kingdom

eligibility_changeATTR Amyloidosis (Transthyretin Amyloidosis)Sep 9thAlnylam PharmaceuticalsNCT05040373
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAngelman SyndromeSep 9thOHB Pediatrics Ltd.NCT07605429
Added 1 new site: Chicago, Illinois

Added 1 new site: Chicago, Illinois

sites_addedAlpha-1 Antitrypsin DeficiencySep 9thTessera Therapeutics, Inc.NCT07227207
Added 1 new site: Rochester, Minnesota

Added 1 new site: Rochester, Minnesota

sites_addedSpinocerebellar AtaxiaSep 8thIntraBio IncNCT07221292
Added 1 new site: Newcastle upon Tyne, United Kingdom

Added 1 new site: Newcastle upon Tyne, United Kingdom

sites_removedSpinal Muscular AtrophySep 8thCelgeneNCT06764485
Reduced from 281 to 212 sites

Reduced from 281 to 212 sites

Enrollment UpdateSickle Cell DiseaseSep 8thSt. Jude Children's Research HospitalNCT06442761
Target enrollment increased from 15 to 20

Target enrollment increased from 15 to 20

eligibility_changeSickle Cell DiseaseSep 8thSt. Jude Children's Research HospitalNCT06442761
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedWilson DiseaseSep 8thPrime Medicine, Inc.NCT07748403
Added 1 new site: San Antonio, Texas

Added 1 new site: San Antonio, Texas

eligibility_changeWaldenström MacroglobulinemiaSep 8thAbbVieNCT07387471
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedTurner SyndromeSep 8thAscendis Pharma A/SNCT07221851
Added 3 new sites: Tübingen, Germany, Iași, Romania, Suwon, South Korea

Added 3 new sites: Tübingen, Germany, Iași, Romania, Suwon, South Korea

Enrollment UpdateSystemic MastocytosisSep 8thFred Hutchinson Cancer CenterNCT03779854
Target enrollment decreased from 68 to 45

Target enrollment decreased from 68 to 45

sites_addedSystemic MastocytosisSep 8thBlueprint Medicines CorporationNCT07264959
Added 4 new sites: Aurora, Colorado, Normal, Illinois, St Louis, Missouri and 1 more

Added 4 new sites: Aurora, Colorado, Normal, Illinois, St Louis, Missouri and 1 more

Enrollment UpdateStargardt DiseaseSep 8thVeonGen Therapeutics GmbHNCT07002398
Target enrollment increased from 15 to 18

Target enrollment increased from 15 to 18

eligibility_changeSpinocerebellar AtaxiaSep 8thLexeo TherapeuticsNCT06865482
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedSpinal Muscular AtrophySep 8thORIC PharmaceuticalsNCT07723248
Added 5 new sites: Jeffersonville, Indiana, Canton, Ohio, Dallas, Texas and 2 more

Added 5 new sites: Jeffersonville, Indiana, Canton, Ohio, Dallas, Texas and 2 more

sites_addedSpinal Muscular AtrophySep 8thBiogenNCT06555419
Added 2 new sites: Phoenix, Arizona, Orlando, Florida

Added 2 new sites: Phoenix, Arizona, Orlando, Florida

eligibility_changeSevere Combined ImmunodeficiencySep 7thNational Institute of Allergy and Infectious Diseases (NIAID)NCT06851767
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPulmonary Arterial HypertensionSep 7thTempus AINCT06911632
Added 5 new sites: Riverside, California, Springfield, Missouri, New York, New York and 2 more

Added 5 new sites: Riverside, California, Springfield, Missouri, New York, New York and 2 more

sites_addedPulmonary Arterial HypertensionSep 7thInsmed IncorporatedNCT07481981
Added 17 new sites: Los Angeles, California, Torrance, California, Rochester, New York and 14 more

Added 17 new sites: Los Angeles, California, Torrance, California, Rochester, New York and 14 more

sites_addedPulmonary Arterial HypertensionSep 7thPulmovant, Inc.NCT07333183
Added 13 new sites: Santa Barbara, California, Torrance, California, Kissimmee, Florida and 10 more

Added 13 new sites: Santa Barbara, California, Torrance, California, Kissimmee, Florida and 10 more

sites_addedPulmonary Arterial HypertensionSep 7thLiquidia Technologies, Inc.NCT07285655
Added 20 new sites: Phoenix, Arizona, Los Angeles, California, San Francisco, California and 17 more

Added 20 new sites: Phoenix, Arizona, Los Angeles, California, San Francisco, California and 17 more

sites_addedPulmonary Arterial HypertensionSep 7thInhibikase TherapeuticsNCT07365332
Added 41 new sites: Scottsdale, Arizona, Beverly Hills, California, Santa Barbara, California and 38 more

Added 41 new sites: Scottsdale, Arizona, Beverly Hills, California, Santa Barbara, California and 38 more

eligibility_changePulmonary Arterial HypertensionSep 7thUniversity of PennsylvaniaNCT07132788
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPolycythemia VeraSep 7thPrelude Therapeutics IncorporatedNCT07469891
Added 1 new site: Barcelona, Spain

Added 1 new site: Barcelona, Spain

sites_addedPolycythemia VeraSep 7thNovartis PharmaceuticalsNCT07357727
Added 1 new site: Adelaide, Australia

Added 1 new site: Adelaide, Australia

sites_addedPolycystic Kidney DiseaseSep 7thCalico Life Sciences LLCNCT06902558
Added 1 new site: New York, New York

Added 1 new site: New York, New York

sites_addedNoonan SyndromeSep 6thAscendis Pharma A/SNCT07221851
Added 3 new sites: Tübingen, Germany, Iași, Romania, Suwon, South Korea

Added 3 new sites: Tübingen, Germany, Iași, Romania, Suwon, South Korea

eligibility_changeNeurofibromatosis Type 1Sep 6thNational Cancer Institute (NCI)NCT06222203
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedNarcolepsy Type 1Sep 6thAlkermes, Inc.NCT07540897
Added 3 new sites: Brandon, Florida, Frisco, Texas, Krakow, Poland

Added 3 new sites: Brandon, Florida, Frisco, Texas, Krakow, Poland

sites_addedNarcolepsy Type 1Sep 6thAlkermes, Inc.NCT07455383
Added 13 new sites: Novi, Michigan, Madison, Wisconsin, Bruges, Belgium and 10 more

Added 13 new sites: Novi, Michigan, Madison, Wisconsin, Bruges, Belgium and 10 more

Enrollment UpdateNarcolepsy Type 1Sep 6thTakedaNCT07299097
Target enrollment increased from 100 to 402

Target enrollment increased from 100 to 402

sites_addedMyotonic DystrophySep 6thDyne TherapeuticsNCT07486934
Added 3 new sites: Palo Alto, California, Fitzroy, Australia, Aarhus, Denmark

Added 3 new sites: Palo Alto, California, Fitzroy, Australia, Aarhus, Denmark

sites_addedMyelofibrosisSep 6thPrelude Therapeutics IncorporatedNCT07469891
Added 1 new site: Barcelona, Spain

Added 1 new site: Barcelona, Spain

sites_addedMyelofibrosisSep 6thNovartis PharmaceuticalsNCT07357727
Added 4 new sites: Jupiter, Florida, Houston, Texas, Adelaide, Australia and 1 more

Added 4 new sites: Jupiter, Florida, Houston, Texas, Adelaide, Australia and 1 more

sites_addedMyelodysplastic SyndromesSep 6thNational Cancer Institute (NCI)NCT05564390
Added 1 new site: Ottawa, Canada

Added 1 new site: Ottawa, Canada

Enrollment UpdateMyelodysplastic SyndromesSep 6thAuron Therapeutics, Inc.NCT06846606
Target enrollment increased from 34 to 69

Target enrollment increased from 34 to 69

eligibility_changeMyelodysplastic SyndromesSep 6thAuron Therapeutics, Inc.NCT06846606
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesSep 6thNational Cancer Institute (NCI)NCT06577441
Added 1 new site: Hines, Illinois

Added 1 new site: Hines, Illinois

Enrollment UpdateMyelodysplastic SyndromesSep 6thFred Hutchinson Cancer CenterNCT03779854
Target enrollment decreased from 68 to 45

Target enrollment decreased from 68 to 45

eligibility_changeMyelodysplastic SyndromesSep 6thNational Cancer Institute (NCI)NCT00843882
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesSep 6thHannah Choe, MDNCT07249346
Added 2 new sites: Birmingham, Alabama, Boston, Massachusetts

Added 2 new sites: Birmingham, Alabama, Boston, Massachusetts

sites_addedMyelodysplastic SyndromesSep 6thTherapeutic Advances in Childhood Leukemia ConsortiumNCT05849662
Added 2 new sites: Charlotte, North Carolina, Dallas, Texas

Added 2 new sites: Charlotte, North Carolina, Dallas, Texas

sites_addedMyasthenia GravisSep 6thCentre Hospitalier Universitaire de NiceNCT07072988
Added 8 new sites: Créteil, France, Garches, France, Grenoble, France and 5 more

Added 8 new sites: Créteil, France, Garches, France, Grenoble, France and 5 more

sites_addedMyasthenia GravisSep 6thAmgenNCT06987539
Added 6 new sites: Philadelphia, Pennsylvania, CABA, Argentina, Ciudad Autonoma de Buenos Aires, Argentina and 3 more

Added 6 new sites: Philadelphia, Pennsylvania, CABA, Argentina, Ciudad Autonoma de Buenos Aires, Argentina and 3 more

eligibility_changeMyasthenia GravisSep 6thAmgenNCT06987539
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyasthenia GravisSep 6thVertex Pharmaceuticals IncorporatedNCT07501702
Added 1 new site: Fatih, Turkey (Türkiye)

Added 1 new site: Fatih, Turkey (Türkiye)

eligibility_changeMyasthenia GravisSep 6thVertex Pharmaceuticals IncorporatedNCT07501702
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyasthenia GravisSep 6thCentre Hospitalier Universitaire de NiceNCT07570589
Added 10 new sites: Angers, France, Boulogne-sur-Mer, France, Créteil, France and 7 more

Added 10 new sites: Angers, France, Boulogne-sur-Mer, France, Créteil, France and 7 more

Enrollment UpdateMyasthenia GravisSep 6thCartesian TherapeuticsNCT06799247
Target enrollment increased from 100 to 128

Target enrollment increased from 100 to 128

sites_addedMyasthenia GravisSep 6thCentre Hospitalier Universitaire de NiceNCT07411963
Added 7 new sites: Bron, France, Garches, France, Le Kremlin-Bicêtre, France and 4 more

Added 7 new sites: Bron, France, Garches, France, Le Kremlin-Bicêtre, France and 4 more

sites_addedMyasthenia GravisSep 6thCandid TherapeuticsNCT07215650
Added 9 new sites: Fuzhou, China, Guangzhou, China, Guangzhou, China and 6 more

Added 9 new sites: Fuzhou, China, Guangzhou, China, Guangzhou, China and 6 more

eligibility_changeMultiple System AtrophySep 6thSynusight Biotech (Shanghai) Co., Ltd.NCT07604116
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple System AtrophySep 6thTeva Branded Pharmaceutical Products R&D LLCNCT07197866
Added 2 new sites: Kansas City, Kansas, Catania, Italy

Added 2 new sites: Kansas City, Kansas, Catania, Italy

sites_addedMultiple SclerosisSep 6thZenas BioPharma (USA), LLCNCT07299019
Added 1 new site: Pozzilli, Italy

Added 1 new site: Pozzilli, Italy

Enrollment UpdateMixed Connective Tissue DiseaseSep 6thFred Hutchinson Cancer CenterNCT03779854
Target enrollment decreased from 68 to 45

Target enrollment decreased from 68 to 45

Enrollment UpdateMesotheliomaSep 6thA2 Biotherapeutics Inc.NCT04981119
Target enrollment increased from 200 to 500

Target enrollment increased from 200 to 500

sites_addedMembranous NephropathySep 6thVertex Pharmaceuticals IncorporatedNCT07204275
Added 3 new sites: Sacramento, California, Shreveport, Louisiana, Nijmegen, Netherlands

Added 3 new sites: Sacramento, California, Shreveport, Louisiana, Nijmegen, Netherlands

Enrollment UpdateMastocytosisSep 6thNational Institute of Allergy and Infectious Diseases (NIAID)NCT00044122
Target enrollment increased from 600 to 700

Target enrollment increased from 600 to 700

Enrollment UpdateMastocytosisSep 6thFred Hutchinson Cancer CenterNCT03779854
Target enrollment decreased from 68 to 45

Target enrollment decreased from 68 to 45

sites_addedMastocytosisSep 6thBlueprint Medicines CorporationNCT07264959
Added 4 new sites: Aurora, Colorado, Normal, Illinois, St Louis, Missouri and 1 more

Added 4 new sites: Aurora, Colorado, Normal, Illinois, St Louis, Missouri and 1 more

sites_addedIgA NephropathySep 5thADARx Pharmaceuticals, Inc.NCT06989359
Added 3 new sites: Bologna, Italy, Kaohsiung City, Taiwan, Leicester, United Kingdom

Added 3 new sites: Bologna, Italy, Kaohsiung City, Taiwan, Leicester, United Kingdom

sites_addedIgA NephropathySep 5thBiogenNCT06935357
Added 2 new sites: Shenyang, China, Bari, Italy

Added 2 new sites: Shenyang, China, Bari, Italy

sites_addedIdiopathic Pulmonary FibrosisSep 5thAbbVieNCT07230288
Added 9 new sites: Box Hill, Australia, Montpellier, France, Rennes, France and 6 more

Added 9 new sites: Box Hill, Australia, Montpellier, France, Rennes, France and 6 more

sites_addedIdiopathic Pulmonary FibrosisSep 5thCumberland PharmaceuticalsNCT05571059
Added 1 new site: Farmington, Connecticut

Added 1 new site: Farmington, Connecticut

eligibility_changeIdiopathic Pulmonary FibrosisSep 5thCumberland PharmaceuticalsNCT05571059
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedIdiopathic Pulmonary FibrosisSep 5thChiesi Farmaceutici S.p.A.NCT07516951
Added 1 new site: Denison, Texas

Added 1 new site: Denison, Texas

sites_addedIdiopathic Pulmonary FibrosisSep 5thUnited TherapeuticsNCT04905693
Added 21 new sites: Buenos Aires, Argentina, Antwerp, Belgium, Liège, Belgium and 18 more

Added 21 new sites: Buenos Aires, Argentina, Antwerp, Belgium, Liège, Belgium and 18 more

sites_addedIdiopathic Pulmonary FibrosisSep 5thTrevi TherapeuticsNCT07671911
Added 10 new sites: Newport Beach, California, Palm Springs, California, Redding, California and 7 more

Added 10 new sites: Newport Beach, California, Palm Springs, California, Redding, California and 7 more

sites_addedHypoparathyroidismSep 5thMBX BiosciencesNCT07699471
Added 3 new sites: Metairie, Louisiana, Albany, New York, Summerville, South Carolina

Added 3 new sites: Metairie, Louisiana, Albany, New York, Summerville, South Carolina

sites_addedHuntington DiseaseSep 5thNovartis PharmaceuticalsNCT07326709
Added 26 new sites: Birmingham, Alabama, Little Rock, Arkansas, Atlanta, Georgia and 23 more

Added 26 new sites: Birmingham, Alabama, Little Rock, Arkansas, Atlanta, Georgia and 23 more

Enrollment UpdateHuntington DiseaseSep 5thHoffmann-La RocheNCT07246941
Target enrollment decreased from 40 to 3

Target enrollment decreased from 40 to 3

sites_addedHuntington DiseaseSep 5thSarepta Therapeutics, Inc.NCT07536061
Added 3 new sites: Westmead, Australia, Gümligen, Switzerland, Cardiff, United Kingdom

Added 3 new sites: Westmead, Australia, Gümligen, Switzerland, Cardiff, United Kingdom

Enrollment UpdateHomozygous Familial HypercholesterolemiaSep 5thFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT06125847
Target enrollment increased from 12 to 21

Target enrollment increased from 12 to 21

eligibility_changeHomozygous Familial HypercholesterolemiaSep 5thFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT06125847
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHodgkin LymphomaSep 5thThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07083154
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHodgkin LymphomaSep 5thMemorial Sloan Kettering Cancer CenterNCT07223021
Target enrollment decreased from 130 to 65

Target enrollment decreased from 130 to 65

eligibility_changeHodgkin LymphomaSep 5thBeOne MedicinesNCT06634589
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 5thMerck Sharp & Dohme LLCNCT07570173
Added 1 new site: Athens, Greece

Added 1 new site: Athens, Greece

sites_addedHodgkin LymphomaSep 5thNational Cancer Institute (NCI)NCT04546399
Added 4 new sites: New Brunswick, New Jersey, Albuquerque, New Mexico, Tulsa, Oklahoma and 1 more

Added 4 new sites: New Brunswick, New Jersey, Albuquerque, New Mexico, Tulsa, Oklahoma and 1 more

sites_addedHodgkin LymphomaSep 5thMerck Sharp & Dohme LLCNCT06395103
Added 1 new site: Calgary, Canada

Added 1 new site: Calgary, Canada

sites_addedHodgkin LymphomaSep 5thAstraZenecaNCT06549595
Added 4 new sites: Chesterfield, Missouri, Wilmington, North Carolina, Cincinnati, Ohio and 1 more

Added 4 new sites: Chesterfield, Missouri, Wilmington, North Carolina, Cincinnati, Ohio and 1 more

sites_addedHodgkin LymphomaSep 5thMedical College of WisconsinNCT07117136
Added 1 new site: Philadelphia, Pennsylvania

Added 1 new site: Philadelphia, Pennsylvania

eligibility_changeHodgkin LymphomaSep 5thMedical College of WisconsinNCT07117136
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 5thJanssen Research & Development, LLCNCT06788509
Added 2 new sites: Copenhagen, Denmark, Odense C, Denmark

Added 2 new sites: Copenhagen, Denmark, Odense C, Denmark

sites_addedHodgkin LymphomaSep 5thDaiichi SankyoNCT07220616
Added 2 new sites: Villejuif, France, Bologna, Italy

Added 2 new sites: Villejuif, France, Bologna, Italy

sites_addedHodgkin LymphomaSep 5thAllogene TherapeuticsNCT06500273
Added 2 new sites: Lone Tree, Colorado, Suwon, South Korea

Added 2 new sites: Lone Tree, Colorado, Suwon, South Korea

Enrollment UpdateHodgkin LymphomaSep 5thNational Cancer Institute (NCI)NCT04739813
Target enrollment decreased from 55 to 34

Target enrollment decreased from 55 to 34

Enrollment UpdateHodgkin LymphomaSep 5thBaylor College of MedicineNCT04288726
Target enrollment increased from 18 to 27

Target enrollment increased from 18 to 27

eligibility_changeHodgkin LymphomaSep 5thSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT03198026
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaSep 5thNational Cancer Institute (NCI)NCT05675410
Added 1 new site: Charlotte, North Carolina

Added 1 new site: Charlotte, North Carolina

sites_addedHereditary Hemorrhagic TelangiectasiaSep 5thAtavistik Bio, IncNCT07601425
Added 1 new site: Phoenix, Arizona

Added 1 new site: Phoenix, Arizona

sites_addedHereditary AngioedemaSep 5thIonis Pharmaceuticals, Inc.NCT07298447
Added 3 new sites: West Allis, Wisconsin, South Brisbane, Australia, Clayton, Australia

Added 3 new sites: West Allis, Wisconsin, South Brisbane, Australia, Clayton, Australia

sites_addedHereditary AngioedemaSep 5thPharvaris Netherlands B.V.NCT06679881
Added 8 new sites: Colorado Springs, Colorado, Wheaton, Illinois, Box Hill, Australia and 5 more

Added 8 new sites: Colorado Springs, Colorado, Wheaton, Illinois, Box Hill, Australia and 5 more

sites_addedHemophilia ASep 4thHoffmann-La RocheNCT07416604
Added 12 new sites: Godoy Cruz, Argentina, Rosario, Argentina, Brussels, Belgium and 9 more

Added 12 new sites: Godoy Cruz, Argentina, Rosario, Argentina, Brussels, Belgium and 9 more

sites_addedGraves’ DiseaseSep 4thYarrow Bioscience, Inc.NCT07682896
Added 3 new sites: Tucson, Arizona, Raleigh, North Carolina, Dallas, Texas

Added 3 new sites: Tucson, Arizona, Raleigh, North Carolina, Dallas, Texas

sites_addedGraves’ DiseaseSep 4thBiogenNCT07722546
Added 3 new sites: Glendale, Arizona, Doral, Florida, Miami, Florida

Added 3 new sites: Glendale, Arizona, Doral, Florida, Miami, Florida

sites_addedGranulomatosis with PolyangiitisSep 4thNovartis PharmaceuticalsNCT06868290
Added 6 new sites: Chicago, Illinois, Durham, North Carolina, Philadelphia, Pennsylvania and 3 more

Added 6 new sites: Chicago, Illinois, Durham, North Carolina, Philadelphia, Pennsylvania and 3 more

sites_addedEpidermolysis BullosaSep 4thParadigm TherapeuticsNCT07482787
Added 1 new site: Charleston, South Carolina

Added 1 new site: Charleston, South Carolina

sites_addedGraves’ DiseaseSep 4thBiohaven Therapeutics Ltd.NCT07661056
Added 14 new sites: Tucson, Arizona, Oakland, California, Fort Myers, Florida and 11 more

Added 14 new sites: Tucson, Arizona, Oakland, California, Fort Myers, Florida and 11 more

eligibility_changeGraves’ DiseaseSep 4thBiohaven Therapeutics Ltd.NCT07661056
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedGraves’ DiseaseSep 4thCandid TherapeuticsNCT07597200
Added 13 new sites: Hefei, China, Beijing, China, Fuzhou, China and 10 more

Added 13 new sites: Hefei, China, Beijing, China, Fuzhou, China and 10 more

sites_addedGeographic AtrophySep 4thAstellas Institute for Regenerative MedicineNCT03178149
Added 1 new site: Portland, Oregon

Added 1 new site: Portland, Oregon

sites_addedGeographic AtrophySep 4thComplement TherapeuticsNCT07144137
Added 3 new sites: Belfast, United Kingdom, Frimley, United Kingdom, Manchester, United Kingdom

Added 3 new sites: Belfast, United Kingdom, Frimley, United Kingdom, Manchester, United Kingdom

sites_addedGeographic AtrophySep 4thADARx Pharmaceuticals, Inc.NCT06990269
Added 46 new sites: Riverside, California, Sutherland, Australia, Sydney, Australia and 43 more

Added 46 new sites: Riverside, California, Sutherland, Australia, Sydney, Australia and 43 more

eligibility_changeFriedreich AtaxiaSep 4thLexeo TherapeuticsNCT06865482
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedFocal EpilepsySep 4thRapport Therapeutics Inc.NCT07563881
Added 1 new site: Asheville, North Carolina

Added 1 new site: Asheville, North Carolina

sites_addedFocal EpilepsySep 4thRapport Therapeutics Inc.NCT07594119
Added 5 new sites: Huntsville, Alabama, Chicago, Illinois, New York, New York and 2 more

Added 5 new sites: Huntsville, Alabama, Chicago, Illinois, New York, New York and 2 more

sites_addedFanconi AnemiaSep 4thDuke Street Bio LtdNCT06458712
Added 3 new sites: Sacramento, California, Lodz, Poland, Pamplona, Spain

Added 3 new sites: Sacramento, California, Lodz, Poland, Pamplona, Spain

sites_addedFabry DiseaseSep 4thAmicus TherapeuticsNCT06904261
Added 1 new site: Sagamihara, Japan

Added 1 new site: Sagamihara, Japan

sites_addedEssential ThrombocythemiaSep 4thPrelude Therapeutics IncorporatedNCT07469891
Added 1 new site: Barcelona, Spain

Added 1 new site: Barcelona, Spain

sites_removedEssential ThrombocythemiaSep 4thIncyte CorporationNCT07623200
Reduced from 180 to 177 sites

Reduced from 180 to 177 sites

sites_addedEssential ThrombocythemiaSep 4thNovartis PharmaceuticalsNCT07357727
Added 4 new sites: Jupiter, Florida, Houston, Texas, Adelaide, Australia and 1 more

Added 4 new sites: Jupiter, Florida, Houston, Texas, Adelaide, Australia and 1 more

sites_addedEpidermolysis BullosaSep 4thParadigm TherapeuticsNCT07482787
Added 1 new site: Redwood City, California

Added 1 new site: Redwood City, California

sites_addedDravet SyndromeSep 3rdIonis Pharmaceuticals, Inc.NCT07531745
Added 2 new sites: Durham, North Carolina, Montreal, Canada

Added 2 new sites: Durham, North Carolina, Montreal, Canada

sites_addedCold Agglutinin DiseaseSep 3rdLakefront Biotherapeutics West LLCNCT07083960
Added 4 new sites: Duarte, California, Washington D.C., District of Columbia, Ann Arbor, Michigan and 1 more

Added 4 new sites: Duarte, California, Washington D.C., District of Columbia, Ann Arbor, Michigan and 1 more

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 3rdRush University Medical CenterNCT06044649
Target enrollment decreased from 460 to 408

Target enrollment decreased from 460 to 408

sites_addedChronic Graft-versus-Host DiseaseSep 3rdAmgenNCT07684235
Added 4 new sites: Skokie, Illinois, Winchester, Virginia, Minato-ku, Japan and 1 more

Added 4 new sites: Skokie, Illinois, Winchester, Virginia, Minato-ku, Japan and 1 more

sites_addedChronic Graft-versus-Host DiseaseSep 3rdMerck Sharp & Dohme LLCNCT05458297
Added 1 new site: Montreal, Canada

Added 1 new site: Montreal, Canada

sites_addedChronic Graft-versus-Host DiseaseSep 3rdTakedaNCT06948318
Added 7 new sites: Hot Springs, Arkansas, Indianapolis, Indiana, Kansas City, Missouri and 4 more

Added 7 new sites: Hot Springs, Arkansas, Indianapolis, Indiana, Kansas City, Missouri and 4 more

sites_addedChronic Graft-versus-Host DiseaseSep 3rdNovartis PharmaceuticalsNCT04877522
Added 2 new sites: Milwaukee, Wisconsin, Kobe, Japan

Added 2 new sites: Milwaukee, Wisconsin, Kobe, Japan

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdVA Office of Research and DevelopmentNCT04887688
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdNational Institute of Allergy and Infectious Diseases (NIAID)NCT06476132
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 3rdSanofiNCT06290141
Added 13 new sites: Centennial, Colorado, Miami Lakes, Florida, New York, New York and 10 more

Added 13 new sites: Centennial, Colorado, Miami Lakes, Florida, New York, New York and 10 more

sites_addedChronic Graft-versus-Host DiseaseSep 3rdNovartis PharmaceuticalsNCT06675864
Added 3 new sites: Mainz, Germany, Barcelona, Spain, Madrid, Spain

Added 3 new sites: Mainz, Germany, Barcelona, Spain, Madrid, Spain

sites_addedChronic Graft-versus-Host DiseaseSep 3rdAbbVieNCT06603558
Added 32 new sites: Busan, South Korea, Busan, South Korea, Busan, South Korea and 29 more

Added 32 new sites: Busan, South Korea, Busan, South Korea, Busan, South Korea and 29 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdHealthPartners InstituteNCT07491861
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedEosinophilic Granulomatosis with PolyangiitisSep 3rdUniversity of PennsylvaniaNCT00315380
Added 2 new sites: Cambridge, United Kingdom, London, United Kingdom

Added 2 new sites: Cambridge, United Kingdom, London, United Kingdom

sites_removedEosinophilic EsophagitisSep 3rdDr. Falk Pharma GmbHNCT06596252
Reduced from 27 to 21 sites

Reduced from 27 to 21 sites

sites_addedDilated CardiomyopathySep 3rdAffinia TherapeuticsNCT07426419
Added 1 new site: Montreal, Canada

Added 1 new site: Montreal, Canada

phase_changeDesmoplastic Small Round Cell TumorSep 3rdNational Cancer Institute (NCI)NCT04616560
Moved from Phase 1, Phase 2 to Phase 2

Moved from Phase 1, Phase 2 to Phase 2

sites_addedCongenital Adrenal HyperplasiaSep 3rdCrinetics Pharmaceuticals Inc.NCT07144163
Added 5 new sites: Gainesville, Florida, Graz, Austria, Hiroshima, Japan and 2 more

Added 5 new sites: Gainesville, Florida, Graz, Austria, Hiroshima, Japan and 2 more

sites_addedCongenital Adrenal HyperplasiaSep 3rdAssistance Publique - Hôpitaux de ParisNCT06900153
Added 3 new sites: Bordeaux, France, Créteil, France, Le Kremlin-Bicêtre, France

Added 3 new sites: Bordeaux, France, Créteil, France, Le Kremlin-Bicêtre, France

sites_addedCongenital Adrenal HyperplasiaSep 3rdCrinetics Pharmaceuticals Inc.NCT07159841
Added 4 new sites: Santiago, Chile, Cologne, Germany, Bialystok, Poland and 1 more

Added 4 new sites: Santiago, Chile, Cologne, Germany, Bialystok, Poland and 1 more

eligibility_changeCommon Variable ImmunodeficiencySep 3rdMemorial Sloan Kettering Cancer CenterNCT06976476
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 3rdJanssen Research & Development, LLCNCT05327114
Added 1 new site: Augusta, Georgia

Added 1 new site: Augusta, Georgia

sites_addedChronic Inflammatory Demyelinating PolyneuropathySep 3rdDianthus TherapeuticsNCT06858579
Added 4 new sites: Serdang, Malaysia, Ankara, Turkey (Türkiye), Hanoi, Vietnam and 1 more

Added 4 new sites: Serdang, Malaysia, Ankara, Turkey (Türkiye), Hanoi, Vietnam and 1 more

sites_addedChronic Graft-versus-Host DiseaseSep 3rdJanssen Research & Development, LLCNCT05963074
Added 1 new site: El Paso, Texas

Added 1 new site: El Paso, Texas

sites_addedChronic Graft-versus-Host DiseaseSep 3rdPfizerNCT07363694
Added 32 new sites: Tampa, Florida, Kansas City, Kansas, Fall River, Massachusetts and 29 more

Added 32 new sites: Tampa, Florida, Kansas City, Kansas, Fall River, Massachusetts and 29 more

sites_addedChronic Graft-versus-Host DiseaseSep 3rdLMU KlinikumNCT05554835
Added 18 new sites: Munich, Germany, Halle, Germany, München, Germany and 15 more

Added 18 new sites: Munich, Germany, Halle, Germany, München, Germany and 15 more

sites_addedChronic Graft-versus-Host DiseaseSep 3rdSanofiNCT07116031
Added 4 new sites: Seattle, Washington, Vancouver, Canada, Turin, Italy and 1 more

Added 4 new sites: Seattle, Washington, Vancouver, Canada, Turin, Italy and 1 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdSanofiNCT07116031
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdCentre Hospitalier Universitaire de Saint EtienneNCT05780762
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseSep 3rdLomond Therapeutics Holdings, Inc.NCT06708897
Added 1 new site: Dallas, Texas

Added 1 new site: Dallas, Texas

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 3rdLomond Therapeutics Holdings, Inc.NCT06708897
Target enrollment increased from 66 to 84

Target enrollment increased from 66 to 84

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdLomond Therapeutics Holdings, Inc.NCT06708897
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdVA Office of Research and DevelopmentNCT06004804
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseSep 3rdSt. Olavs HospitalNCT05372822
Target enrollment decreased from 87 to 40

Target enrollment decreased from 87 to 40

sites_addedChronic Graft-versus-Host DiseaseSep 3rdFondazione Don Carlo Gnocchi ETSNCT06547827
Added 14 new sites: Bergamo, Italy, Catania, Italy, Catanzaro, Italy and 11 more

Added 14 new sites: Bergamo, Italy, Catania, Italy, Catanzaro, Italy and 11 more

eligibility_changeChronic Graft-versus-Host DiseaseSep 3rdUniversity of MinnesotaNCT06808048
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedCholangiocarcinomaSep 3rdUNICANCERNCT06529718
Added 1 new site: Grenoble, France

Added 1 new site: Grenoble, France

Enrollment UpdateAmyotrophic Lateral SclerosisSep 2ndDallas VA Medical CenterNCT04244630
Target enrollment decreased from 60 to 21

Target enrollment decreased from 60 to 21

sites_addedAplastic AnemiaSep 2ndMedical College of WisconsinNCT07227155
Added 8 new sites: Duarte, California, Atlanta, Georgia, Chicago, Illinois and 5 more

Added 8 new sites: Duarte, California, Atlanta, Georgia, Chicago, Illinois and 5 more

sites_addedAmyotrophic Lateral SclerosisSep 2ndZydus Therapeutics Inc.NCT07023835
Added 32 new sites: Caulfield South, Australia, Sydney, Australia, Southport, Australia and 29 more

Added 32 new sites: Caulfield South, Australia, Sydney, Australia, Southport, Australia and 29 more

sites_addedAmyotrophic Lateral SclerosisSep 2ndInsmed Gene Therapy LLCNCT07290062
Added 2 new sites: Baltimore, Maryland, Worcester, Massachusetts

Added 2 new sites: Baltimore, Maryland, Worcester, Massachusetts

sites_addedAdrenocortical CarcinomaSep 2ndNational Cancer Institute (NCI)NCT06900595
Added 1 new site: Phoenix, Arizona

Added 1 new site: Phoenix, Arizona

sites_addedAchondroplasiaSep 2ndTyra Biosciences, IncNCT06842355
Added 1 new site: London, United Kingdom

Added 1 new site: London, United Kingdom

eligibility_changeThalassemiaSep 1stNational Heart, Lung, and Blood Institute (NHLBI)NCT05904093
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeSickle Cell DiseaseSep 1stNational Heart, Lung, and Blood Institute (NHLBI)NCT05904093
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedUrea Cycle DisordersSep 1stiECURE, Inc.NCT06805695
Added 2 new sites: Aurora, Colorado, New York, New York

Added 2 new sites: Aurora, Colorado, New York, New York

sites_addedThalassemiaSep 1stAgios Pharmaceuticals, Inc.NCT07506863
Added 2 new sites: New York, New York, Philadelphia, Pennsylvania

Added 2 new sites: New York, New York, Philadelphia, Pennsylvania

sites_addedThalassemiaSep 1stAgios Pharmaceuticals, Inc.NCT07517133
Added 3 new sites: Palo Alto, California, New York, New York, Philadelphia, Pennsylvania

Added 3 new sites: Palo Alto, California, New York, New York, Philadelphia, Pennsylvania

sites_addedStargardt DiseaseSep 1stAlkeus Pharmaceuticals, Inc.NCT07419334
Added 5 new sites: Aurora, Colorado, Grand Rapids, Michigan, Columbus, Ohio and 2 more

Added 5 new sites: Aurora, Colorado, Grand Rapids, Michigan, Columbus, Ohio and 2 more